Zlotogora    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Multiple    B-AutosomalDominantDisease114162025
mucosal    I-AutosomalDominantDisease114162025
neuromata    I-AutosomalDominantDisease114162025

Multiple    B-AutosomalDominantDisease114162025
endocrine    I-AutosomalDominantDisease114162025
neoplasia    I-AutosomalDominantDisease114162025
type    I-AutosomalDominantDisease114162025
2b    I-AutosomalDominantDisease114162025

Multiple    B-AutosomalDominantDisease114162025
mucosal    I-AutosomalDominantDisease114162025
neuroma    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Central    B-AutosomalDominantDisease114162025
core    I-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025

One    O
source    O
includes    O
nemaline    O
myopathy    O
,    O
myotubular    O
myopathy    O
,    O
central    B-AutosomalDominantDisease114162025
core    I-AutosomalDominantDisease114162025
myopathy    I-AutosomalDominantDisease114162025
,    O
congenital    O
fiber    O
type    O
disproportion    O
,    O
and    O
multicore    O
myopathy    O
.    O

Worth    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Laryngeal    O
cleft    O
can    O
also    O
be    O
a    O
component    O
of    O
other    O
genetic    O
syndromes    O
,    O
including    O
Pallister-Hall    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
and    O
G    O
syndrome    O
(    O
Opitz    O
-    O
Friaz    O
syndrome    O
)    O
.    O

Other    O
entities    O
associated    O
with    O
an    O
imperforate    O
anus    O
are    O
trisomies    O
18    O
and    O
21    O
,    O
the    O
cat    O
-    O
eye    O
syndrome    O
(    O
partial    O
trisomy    O
or    O
tetrasomy    O
of    O
a    O
maternally    O
derived    O
number    O
22    O
chromosome    O
)    O
,    O
Baller    O
-    O
Gerold    O
syndrome    O
,    O
Currarino    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
caudal    O
regression    O
syndrome    O
,    O
FG    O
syndrome    O
,    O
Johanson    O
-    O
Blizzard    O
syndrome    O
,    O
McKusick    O
-    O
Kaufman    O
syndrome    O
,    O
Pallister-Hall    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
short    O
rib    O
-    O
polydactyly    O
syndrome    O
type    O
1    O
,    O
Townes    O
-    O
Brocks    O
syndrome    O
,    O
13q    O
deletion    O
syndrome    O
,    O
urorectal    O
septum    O
malformation    O
sequence    O
,    O
and    O
the    O
OEIS    O
complex    O
(    O
omphalocele    O
,    O
exstrophy    O
of    O
the    O
cloaca    O
,    O
imperforate    O
anus    O
,    O
spinal    O
defects    O
)    O
.    O

Dermatopathic    B-AutosomalDominantDisease114162025
pigmentosa    I-AutosomalDominantDisease114162025
reticularis    I-AutosomalDominantDisease114162025

Dermatopathia    B-AutosomalDominantDisease114162025
pigmentosa    I-AutosomalDominantDisease114162025
reticularis    I-AutosomalDominantDisease114162025
,    O
a    O
rare    O
form    O
of    O
ectodermal    O
dysplasia    O

Among    O
the    O
differential    O
diagnosis    O
are    O
hereditary    O
ostoesclerosing    O
dysplasias    O
such    O
as    O
;    O
neuropathic    O
infantile    O
osteopetrosis    O
,    O
infantile    O
osteopetrosis    O
with    O
renal    O
tubular    O
acidosis    O
,    O
infantile    O
osteopetrosis    O
with    O
immunodeficiency    O
,    O
infantile    O
osteopetrosis    O
with    O
leukocyte    O
adhesion    O
deficiency    O
syndrome    O
(    O
LAD    O
-    O
III    O
)    O
,    O
pyknodysostosis    O
(    O
osteopetrosis    O
acro    O
-    O
osteolytica    O
)    O
,    O
osteopoikilosis    O
(    O
Buschke–Ollendorff    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
)    O
,    O
osteopathia    O
striata    O
with    O
cranial    O
sclerosis    O
,    O
mixed    O
sclerosing    O
skeletal    O
dysplasias    O
,    O
progressive    O
diaphyseal    O
dysplasia    O
(    O
Camurati–Engelmann    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
)    O
,    O
SOST    O
-    O
related    O
sclerosing    O
skeletal    O
dysplasias    O
.    O

Mutations    O
in    O
the    O
"    O
LEMD3    O
"    O
gene    O
have    O
been    O
linked    O
to    O
several    O
genetic    O
diseases    O
such    O
as    O
osteopoikilosis    O
,    O
melorheostosis    O
and    O
Buschke-Ollendorff    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Branchio-oto-renal    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
(    O
BOR    O
)    O
,    O
also    O
known    O
as    O
branchiootorenal    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
or    O
BOR    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
is    O
an    O
autosomal    O
dominant    O
genetic    O
disorder    O
involving    O
the    O
kidneys    O
,    O
ears    O
,    O
and    O
neck    O
.    O

It    O
is    O
often    O
misdiagnosed    O
as    O
branchio-oto-renal    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
because    O
of    O
their    O
similarities    O
in    O
symptoms    O
.    O

Mutations    O
in    O
the    O
FLNB    O
gene    O
are    O
involved    O
in    O
several    O
lethal    O
bone    O
dysplasias    O
,    O
including    O
boomerang    B-AutosomalDominantDisease114162025
dysplasia    I-AutosomalDominantDisease114162025
and    O
atelosteogenesis    O
type    O
I.    O

Thakker    O
's    O
research    O
investigates    O
neuroendocrine    O
tumours    O
such    O
as    O
multiple    B-AutosomalDominantDisease114162025
endocrine    I-AutosomalDominantDisease114162025
neoplasia    I-AutosomalDominantDisease114162025
type    I-AutosomalDominantDisease114162025
1    I-AutosomalDominantDisease114162025
(MEN1)    I-AutosomalDominantDisease114162025
and    O
the    O
molecular    O
basis    O
of    O
disorders    O
of    O
calcium    O
homeostasis    O
.    O

M13    O
phage    O
-    O
malformation    O
-    O
mapping    O
-    O
marker    O
-    O
melanoma    O
-    O
melting    O
-    O
Johann    O
Mendel    O
-    O
Mendelian    O
inheritance    O
-    O
message    O
-    O
messenger    O
RNA    O
-    O
metaphase    O
-    O
microarray    O
technology    O
-    O
microsatellite    O
-    O
missense    O
mutation    O
-    O
mitochondrial    O
DNA    O
-    O
mobility    O
shift    O
-    O
molecular    O
weight    O
size    O
marker    O
-    O
monoclonal    O
antibody    O
-    O
monosomy    O
-    O
mouse    O
model    O
-    O
mRNA    O
-    O
multicistronic    O
message    O
-    O
multicopy    O
plasmid    O
-    O
multiple    O
cloning    O
site    O
-    O
multiple    B-AutosomalDominantDisease114162025
endocrine    I-AutosomalDominantDisease114162025
neoplasia,    I-AutosomalDominantDisease114162025
type    I-AutosomalDominantDisease114162025
1    I-AutosomalDominantDisease114162025
-    O
mutation    O
-    O

Adenomas    O
of    O
the    O
anterior    O
pituitary    O
gland    O
are    O
a    O
major    O
clinical    O
feature    O
of    O
multiple    B-AutosomalDominantDisease114162025
endocrine    I-AutosomalDominantDisease114162025
neoplasia    I-AutosomalDominantDisease114162025
type    I-AutosomalDominantDisease114162025
1    I-AutosomalDominantDisease114162025
(    O
MEN1    O
)    O
,    O
a    O
rare    O
inherited    O
endocrine    O
syndrome    O
that    O
affects    O
1    O
person    O
in    O
every    O
30,000    O
.    O

Menin    O
is    O
a    O
putative    O
tumor    O
suppressor    O
associated    O
with    O
multiple    B-AutosomalDominantDisease114162025
endocrine    I-AutosomalDominantDisease114162025
neoplasia    I-AutosomalDominantDisease114162025
type    I-AutosomalDominantDisease114162025
1    I-AutosomalDominantDisease114162025
(    O
MEN-1    O
syndrome    O
)    O
.    O

Familial    O
loss    O
of    O
one    O
copy    O
of    O
MEN1    O
is    O
seen    O
In    O
association    O
with    O
MEN-1    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Progressive    B-AutosomalDominantDisease114162025
diaphyseal    I-AutosomalDominantDisease114162025
dysplasia    I-AutosomalDominantDisease114162025

Camurati-Engelmann    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Multiple    B-AutosomalDominantDisease114162025
endocrine    I-AutosomalDominantDisease114162025
neoplasia    I-AutosomalDominantDisease114162025

Paragangliomas    O
may    O
also    O
occur    O
in    O
MEN    B-AutosomalDominantDisease114162025
type    O
2A    O
and    O
2B.    O
They    O
are    O
seen    O
in    O
at    O
a    O
higher    O
incidence    O
in    O
people    O
living    O
at    O
high    O
altitude    O
.    O

Such    O
co    O
-    O
occurrences    O
are    O
usually    O
seen    O
in    O
patients    O
carrying    O
hereditary    O
syndromes    O
like    O
multiple    B-AutosomalDominantDisease114162025
endocrine    I-AutosomalDominantDisease114162025
neoplasia    I-AutosomalDominantDisease114162025
(    O
MEN    O
)    O
,    O
neurofibromatosis    O
1    O
(    O
NF1    O
)    O
,    O
or    O
von    B-AutosomalDominantDisease114162025
Hippel-Lindau    I-AutosomalDominantDisease114162025
(    O
VHL    O
)    O
disease    O
.    O

multiple    B-AutosomalDominantDisease114162025
endocrine    I-AutosomalDominantDisease114162025
neoplasia    I-AutosomalDominantDisease114162025
type    O
I    O
,    O

In    O
July    O
2013    O
,    O
the    O
former    O
Mediacorp    O
artiste    O
was    O
diagnosed    O
with    O
multiple    B-AutosomalDominantDisease114162025
endocrine    I-AutosomalDominantDisease114162025
neoplasia    I-AutosomalDominantDisease114162025
(MEN)    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
and    O
was    O
later    O
confirmed    O
to    O
have    O
Neuroendocrine    O
cancer    O
tumors    O
in    O
her    O
liver    O
.    O

Nail–patella    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
=    O
Big    O
toe    O
with    O
most    O
of    O
the    O
toenail    O
missing    O
;    O
only    O
the    O
nail    O
's    O
root    O
is    O
present    O
.    O

Nail    B-AutosomalDominantDisease114162025
patella    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Nail-patella    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
(    O
ILDS    O
Q87.230    O
)    O

Tietz    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

von    B-AutosomalDominantDisease114162025
Hippel-Lindau    I-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
(    O
EUROCAT    O
Q85.82    O
)    O

He    O
also    O
conducted    O
research    O
of    O
eye    O
diseases    O
;    O
in    O
1874    O
he    O
made    O
an    O
early    O
observation    O
of    O
what    O
would    O
be    O
later    O
known    O
as    O
Von    B-AutosomalDominantDisease114162025
Hippel-Lindau    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
and    O
in    O
1878    O
he    O
provided    O
an    O
early    O
clinical    O
description    O
of    O
proptosis    O
in    O
infantile    O
scurvy    O
.    O

It    O
is    O
usually    O
found    O
in    O
the    O
head    O
of    O
the    O
pancreas    O
,    O
and    O
may    O
be    O
associated    O
with    O
von    B-AutosomalDominantDisease114162025
Hippel-Lindau    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

This    O
tumor    O
shows    O
a    O
very    O
high    O
association    O
with    O
von    B-AutosomalDominantDisease114162025
Hippel-Lindau    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
(    O
VHL    O
)    O
.    O

Such    O
co    O
-    O
occurrences    O
are    O
usually    O
seen    O
in    O
patients    O
carrying    O
hereditary    O
syndromes    O
like    O
multiple    B-AutosomalDominantDisease114162025
endocrine    I-AutosomalDominantDisease114162025
neoplasia    I-AutosomalDominantDisease114162025
(    O
MEN    O
)    O
,    O
neurofibromatosis    O
1    O
(    O
NF1    O
)    O
,    O
or    O
von    B-AutosomalDominantDisease114162025
Hippel-Lindau    I-AutosomalDominantDisease114162025
(    O
VHL    O
)    O
disease    O
.    O

She    O
later    O
meets    O
Henry    O
Burton    O
,    O
a    O
patient    O
with    O
the    O
rare    O
genetic    O
condition    O
Von    B-AutosomalDominantDisease114162025
Hippel-Lindau    I-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
who    O
can    O
no    O
longer    O
afford    O
to    O
pay    O
for    O
his    O
medical    O
care    O
.    O

Eugen    O
von    O
Hippel    O
(    O
1867–1939    O
)    O
,    O
a    O
German    O
ophthalmologist    O
,    O
his    O
son    O
(    O
discoverer    O
of    O
Von    B-AutosomalDominantDisease114162025
Hippel-Lindau    I-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
)    O

Factors    O
that    O
increase    O
the    O
likelihood    O
of    O
this    O
cancer    O
include    O
Li    O
-    O
Fraumeni    O
syndrome    O
,    O
type    O
one    O
Neurofibromatosis    O
,    O
Beckwith    O
-    O
Wiedemann    O
syndrome    O
,    O
Costello    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
and    O
Noonan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Costello    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Warts–hypogammaglobulinemia–infections–myelokathexis    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
(    O
WHIM    O
syndrome    O
)    O

It    O
has    O
been    O
associated    O
with    O
WHIM    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Saethre–Chotzen    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
(    O
SCS    O
)    O
,    O
also    O
known    O
as    O
Acrocephalosyndactyly    B-AutosomalDominantDisease114162025
type    I-AutosomalDominantDisease114162025
III    I-AutosomalDominantDisease114162025
is    O
a    O
rare    O
congenital    O
disorder    O
associated    O
with    O
craniosynostosis    O
(    O
premature    O
closure    O
of    O
one    O
or    O
more    O
of    O
the    O
sutures    O
between    O
the    O
bones    O
of    O
the    O
skull    O
)    O
.    O

Upington    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
also    O
called    O
Perthes-like    B-AutosomalDominantDisease114162025
hip    I-AutosomalDominantDisease114162025
disease,    I-AutosomalDominantDisease114162025
enchondromata,    I-AutosomalDominantDisease114162025
ecchondromata    I-AutosomalDominantDisease114162025
,    O
and    O
familial    B-AutosomalDominantDisease114162025
dyschondroplasia    I-AutosomalDominantDisease114162025
,    O
is    O
an    O
extremely    O
rare    O
autosomal    O
dominant    O
malformation    O
disorder    O
.    O

In    O
addition    O
to    O
conducting    O
his    O
own    O
research    O
(    O
Flynn    B-AutosomalDominantDisease114162025
Aird    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
bears    O
his    O
name    O
)    O
,    O
Aird    O
developed    O
the    O
department    O
into    O
a    O
leading    O
academic    O
center    O
for    O
study    O
of    O
the    O
brain    O
sciences    O
,    O
drawing    O
future    O
Nobel    O
laureate    O
Stanley    O
Prusiner    O
as    O
a    O
resident    O
late    O
during    O
Aird    O
's    O
tenure    O
.    O

Timothy    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Elliptocytosis    B-AutosomalDominantDisease114162025
(    O
congenital    O
)    O

Southeast    O
Asian    O
ovalocytosis    O
is    O
a    O
form    O
of    O
hereditary    B-AutosomalDominantDisease114162025
elliptocytosis    I-AutosomalDominantDisease114162025
common    O
in    O
some    O
communities    O
in    O
Malaysia    O
and    O
Papua    O
New    O
Guinea    O
,    O
as    O
it    O
confers    O
some    O
resistance    O
to    O
cerebral    O
Falciparum    O
Malaria    O
.    O

Hereditary    B-AutosomalDominantDisease114162025
elliptocytosis    I-AutosomalDominantDisease114162025

The    O
contiguous    O
gene    O
deletion    O
syndrome    O
is    O
characterised    O
by    O
Alport    O
syndrome    O
(    O
A    O
)    O
,    O
intellectual    O
disability    O
(    O
M    O
)    O
,    O
midface    O
hypoplasia    O
(    O
M    O
)    O
,    O
and    O
elliptocytosis    B-AutosomalDominantDisease114162025
(    O
E    O
)    O
,    O
as    O
well    O
as    O
generalized    O
hypoplasia    O
and    O
cardiac    O
abnormalities    O
.    O

The    O
differential    O
diagnosis    O
includes    O
other    O
oral    O
white    O
lesions    O
such    O
as    O
Leukoplakia    O
,    O
squamous    O
cell    O
carcinoma    O
,    O
oral    O
candidiasis    O
,    O
lichen    O
planus    O
,    O
white    B-AutosomalDominantDisease114162025
sponge    I-AutosomalDominantDisease114162025
nevus    I-AutosomalDominantDisease114162025
and    O
contact    O
stomatitis    O
.    O

In    O
the    O
mouth    O
it    O
appears    O
similar    O
to    O
white    B-AutosomalDominantDisease114162025
sponge    I-AutosomalDominantDisease114162025
nevus    I-AutosomalDominantDisease114162025
,    O
with    O
painless    O
,    O
diffuse    O
,    O
folded    O
and    O
spongy    O
white    O
plaques    O
.    O

Spinocerebellar    B-AutosomalDominantDisease114162025
ataxia    I-AutosomalDominantDisease114162025
type-6    I-AutosomalDominantDisease114162025

It    O
has    O
been    O
suggested    O
that    O
this    O
syndrome    O
,    O
AEC    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
and    O
Rapp–    O

Hay-Wells    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Schmitt    B-AutosomalDominantDisease114162025
Gillenwater    I-AutosomalDominantDisease114162025
Kelly    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
is    O
a    O
rare    O
autosomal    O
dominant    O
congenital    O
disorder    O
consisting    O
of    O
radial    O
hypoplasia    O
,    O
triphalangeal    O
thumbs    O
,    O
hypospadias    O
,    O
and    O
maxillary    O
diastema    O
.    O

Porphyria    B-AutosomalDominantDisease114162025
cutanea    I-AutosomalDominantDisease114162025
tarda    I-AutosomalDominantDisease114162025

Sporadic    B-AutosomalDominantDisease114162025
porphyria    I-AutosomalDominantDisease114162025
cutanea    I-AutosomalDominantDisease114162025
tarda    I-AutosomalDominantDisease114162025
(    O
ILDS    O
E80.110    O
)    O

Familial    B-AutosomalDominantDisease114162025
porphyria    I-AutosomalDominantDisease114162025
cutanea    I-AutosomalDominantDisease114162025
tarda    I-AutosomalDominantDisease114162025
(    O
ILDS    O
E80.120    O
)    O

Pseudoporphyria    O
(    O
also    O
known    O
as    O
"    O
Pseudoporphyria    O
cutanea    O
tarda    O
"    O
)    O
is    O
a    O
bullous    O
photosensitivity    O
that    O
clinically    O
and    O
histologically    O
mimics    O
porphyria    B-AutosomalDominantDisease114162025
cutanea    I-AutosomalDominantDisease114162025
tarda    I-AutosomalDominantDisease114162025
.    O

Chloracne    O
is    O
very    O
often    O
seen    O
in    O
combination    O
with    O
hyperhidrosis    O
(    O
clammy    O
,    O
sweaty    O
skin    O
)    O
and    O
porphyria    B-AutosomalDominantDisease114162025
cutanea    I-AutosomalDominantDisease114162025
tarda    I-AutosomalDominantDisease114162025
(    O
a    O
skin    O
condition    O
of    O
increased    O
pigmentation    O
,    O
hair    O
coarsening    O
and    O
blistering    O
)    O
.    O

Porphyria    B-AutosomalDominantDisease114162025
cutanea    I-AutosomalDominantDisease114162025
tarda    I-AutosomalDominantDisease114162025
.    O

Arakawa's    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
II    I-AutosomalDominantDisease114162025

Other    O
conditions    O
that    O
can    O
produce    O
similar    O
symptoms    O
include    O
mandibuloacral    O
dysplasia    O
,    O
pyknodysostosis    O
,    O
osteogenesis    O
imperfecta    O
,    O
and    O
Hajdu-Cheney    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Hajdu–Cheney    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Myelokathexis    B-AutosomalDominantDisease114162025

Platyspondylic    B-AutosomalDominantDisease114162025
lethal    I-AutosomalDominantDisease114162025
skeletal    I-AutosomalDominantDisease114162025
dysplasia,    I-AutosomalDominantDisease114162025
Torrance    I-AutosomalDominantDisease114162025
type    I-AutosomalDominantDisease114162025
:    O
Fewer    O
than    O
10    O
mutations    O
in    O
the    O
COL2A1    O
gene    O
have    O
been    O
identified    O
in    O
people    O
with    O
platyspondylic    O
lethal    O
skeletal    O
dysplasia    O
,    O
Torrance    O
type    O
.    O

Best    O
’s    O
vitelliform    B-AutosomalDominantDisease114162025
macular    I-AutosomalDominantDisease114162025
dystrophy    I-AutosomalDominantDisease114162025
(    O
BVMD    O
)    O
is    O
one    O
of    O
the    O
most    O
common    O
Best1-associated    O
diseases    O
.    O

Adult    O
-    O
onset    O
vitelliform    B-AutosomalDominantDisease114162025
macular    I-AutosomalDominantDisease114162025
dystrophy    I-AutosomalDominantDisease114162025
(    O
AVMD    O
)    O
consists    O
of    O
lesions    O
similar    O
to    O
BVMD    O
on    O
the    O
retina    O
.    O

Mutations    O
in    O
ATN1    O
are    O
associated    O
with    O
a    O
form    O
of    O
trinucleotide    O
repeat    O
disorder    O
known    O
as    O
"    O
dentatorubral-pallidoluysian    B-AutosomalDominantDisease114162025
atrophy    I-AutosomalDominantDisease114162025
"    O
or    O
"    O
dentatorubropallidoluysian    O
atrophy    O
"    O
.    O

DRPLA    B-AutosomalDominantDisease114162025
is    O
a    O
rare    O
trinucleotide    O
repeat    O
disorder    O
(    O
polyglutamine    O
disease    O
)    O
that    O
can    O
be    O
juvenile    O
-    O
onset    O
(    O
40    O
years    O
)    O
.    O

A    O
very    O
rare    O
medical    O
condition    O
,    O
adermatoglyphia    B-AutosomalDominantDisease114162025
,    O
is    O
characterized    O
by    O
the    O
absence    O
of    O
fingerprints    O
.    O

Mutations    O
in    O
CBP    O
,    O
and    O
to    O
a    O
lesser    O
extent    O
p300    O
,    O
are    O
the    O
cause    O
of    O
Rubinstein-Taybi    B-AutosomalDominantDisease114162025
Syndrome    I-AutosomalDominantDisease114162025
,    O
which    O
is    O
characterized    O
by    O
severe    O
mental    O
retardation    O
.    O

Rubinstein-Taybi    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
(    O
EUROCAT    O
Q87.23    O
)    O

Rubinstein-Taybi    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
a    O
syndrome    O
characterized    O
by    O
unusual    O
facial    O
traits    O
and    O
broad    O
thumbs    O
and    O
toes    O
.    O

Rubinstein-Tabyi    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
causes    O
mental    O
retardation    O
through    O
possible    O
mutations    O
in    O
CREB    O
-    O
binding    O
protein    O
and    O
p300    O
.    O

Mutations    O
in    O
this    O
gene    O
cause    O
Rubinstein-Taybi    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
(    O
RTS    O
)    O
.    O

There    O
is    O
evidence    O
that    O
the    O
autosomal    O
dominant    O
disorder    O
Greig    B-AutosomalDominantDisease114162025
cephalopolysyndactyly    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
(    O
GCPS    O
)    O
that    O
affects    O
limb    O
and    O
craniofacial    O
development    O
in    O
humans    O
is    O
caused    O
by    O
a    O
translocations    O
within    O
the    O
GLI3    O
gene    O
.    O

Greig    B-AutosomalDominantDisease114162025
cephalopolysyndactyly    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

renal    O
cancer    O
is    O
part    O
of    O
a    O
rare    O
,    O
genetic    O
disorder    O
known    O
as    O
Birt-Hogg-Dubé    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Birt-Hogg-Dubé    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025

Guthrie    O
's    O
son    O
,    O
Arlo    O
,    O
said    O
that    O
because    O
of    O
Woody    O
's    O
illness    B-AutosomalDominantDisease114162025
and    O
early    O
death    O
,    O
Arlo    O
never    O
really    O
got    O
to    O
know    O
him    O
,    O
but    O
learned    O
his    O
father    O
's    O
songs    O
and    O
performing    O
style    O
from    O
Elliott    O
.    O
Elliott    O
's    O
guitar    O
and    O
his    O
mastery    O
of    O
Guthrie    O
's    O
material    O
had    O
a    O
big    O
impact    O
on    O
Bob    O
Dylan    O
when    O
he    O
lived    O
in    O
Minneapolis    O
.    O

By    O
My    O
Very    O
Self    O
,    O
"    O
a    O
film    O
about    O
her    O
sister    O
Nina    O
,    O
who    O
is    O
bipolar    O
,    O
and    O
her    O
father    O
,    O
who    O
has    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

Thus    O
we    O
accumulate    O
damages    O
to    O
our    O
body    O
as    O
we    O
age    O
and    O
harbour    O
late    O
-    O
onset    O
diseases    O
such    O
as    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
which    O
have    O
minimum    O
impact    O
on    O
the    O
evolutionary    O
success    O
of    O
our    O
gene    O
overlords    O
.    O

Huntington's    B-AutosomalDominantDisease114162025
Corea    I-AutosomalDominantDisease114162025
is    O
used    O
to    O
discuss    O
the    O
use    O
of    O
a    O
particular    O
sequence    O
on    O
Chromosome    O
Four    O
to    O
cause    O
traumatic    O
health    O
consequences    O
.    O

Huntington's    B-AutosomalDominantDisease114162025
chorea    I-AutosomalDominantDisease114162025

This    O
enzyme    O
participates    O
in    O
3    O
metabolic    O
pathways    O
:    O
ubiquitin    O
-    O
mediated    O
proteolysis    O
,    O
Parkinson    O
's    O
disease    O
,    O
and    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

Various    O
studies    O
have    O
shown    O
the    O
role    O
of    O
astrocytes    O
in    O
diseases    O
such    O
as    O
Alzheimer    O
's    O
,    O
amyotrophic    O
lateral    O
sclerosis    O
(    O
ALS    O
)    O
,    O
Parkinson    O
's    O
,    O
and    O
Huntington's    B-AutosomalDominantDisease114162025
.    O

Several    O
other    O
classes    O
of    O
amyloid    O
proteins    O
also    O
form    O
ion    O
channels    O
,    O
including    O
proteins    O
implicated    O
in    O
type    O
II    O
diabetes    O
mellitus    O
,    O
prion    O
diseases    O
,    O
Parkinson    O
's    O
disease    O
,    O
and    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

His    O
scientific    O
activities    O
where    O
very    O
versatile    O
ranging    O
from    O
moral    O
insanity    O
and    O
dementia    O
to    O
epilepsy    O
,    O
progressive    O
paralysis    O
and    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

Dementia    O
in    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025

Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025

In    O
the    O
season    O
four    O
episode    O
"    O
You    O
Do    O
n't    O
Want    O
to    O
Know    O
"    O
,    O
Thirteen    O
tells    O
House    O
that    O
her    O
mother    O
died    O
from    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
;    O
a    O
test    O
she    O
performs    O
several    O
episodes    O
later    O
confirms    O
she    O
carries    O
the    O
gene    O
.    O

Thirteen    O
has    O
a    O
50/50    O
chance    O
of    O
having    O
inherited    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
from    O
her    O
mother    O
,    O
but    O
she    O
initially    O
refuses    O
to    O
be    O
tested    O
for    O
it    O
as    O
not    O
knowing    O
allows    O
her    O
to    O
live    O
with    O
hope    O
.    O

Throughout    O
the    O
fourth    O
season    O
,    O
the    O
possibility    O
of    O
Thirteen    O
having    O
inherited    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
from    O
her    O
mother    O
becomes    O
a    O
source    O
of    O
tension    O
between    O
her    O
and    O
House    O
.    O

Alternatively    O
,    O
overexpression    O
of    O
Hsp70    O
can    O
mitigate    O
damage    O
from    O
ischemia    O
-    O
reperfusion    O
in    O
cardiac    O
muscle    O
,    O
as    O
well    O
damage    O
from    O
neurodegenerative    O
diseases    O
,    O
such    O
as    O
Alzheimer    O
’s    O
disease    O
,    O
Parkinson    O
’s    O
disease    O
,    O
Huntington’s    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
and    O
spinocerebellar    B-AutosomalDominantDisease114162025
ataxias    I-AutosomalDominantDisease114162025
,    O
and    O
aging    O
and    O
cell    O
senescence    O
,    O
as    O
observed    O
in    O
centenarians    O
subjected    O
to    O
heat    O
shock    O
challenge    O
.    O

The    O
group    O
’s    O
ultimate    O
goal    O
is    O
to    O
find    O
new    O
therapies    O
for    O
Parkinson    O
's    O
disease    O
and    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

discovered    O
a    O
method    O
(    O
non    O
-    O
disclosing    O
preimplantation    O
genetic    O
testing    O
)    O
for    O
the    O
effective    O
prevention    O
of    O
Huntington    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
;    O

Diseases    O
that    O
may    O
present    O
similar    O
to    O
an    O
anxiety    O
disorder    O
,    O
including    O
certain    O
endocrine    O
diseases    O
(    O
hypo-    O
and    O
hyperthyroidism    O
,    O
hyperprolactinemia    O
)    O
,    O
metabolic    O
disorders    O
(    O
diabetes    O
)    O
,    O
deficiency    O
states    O
(    O
low    O
levels    O
of    O
vitamin    O
D    O
,    O
B2    O
,    O
B12    O
,    O
folic    O
acid    O
)    O
,    O
gastrointestinal    O
diseases    O
(    O
celiac    O
disease    O
,    O
non    O
-    O
celiac    O
gluten    O
sensitivity    O
,    O
inflammatory    O
bowel    O
disease    O
)    O
,    O
heart    O
diseases    O
,    O
blood    O
diseases    O
(    O
anemia    O
)    O
,    O
and    O
brain    O
degenerative    O
diseases    O
(    O
Parkinson    O
's    O
disease    O
,    O
dementia    O
,    O
multiple    O
sclerosis    O
,    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
)    O
.    O

In    O
medicine    O
(    O
in    O
general    O
)    O
diseases    O
are    O
defined    O
in    O
terms    O
of    O
a    O
multitude    O
of    O
criteria    O
,    O
these    O
include    O
:    O
(    O
a    O
)    O
"    O
morbid    O
anatomy    O
"    O
,    O
e.g.    O
,    O
mitral    O
stenosis    O
,    O
cholecystitis    O
;    O
(    O
b    O
)    O
"    O
histologically    O
"    O
,    O
e.g.    O
,    O
most    O
cancers    O
,    O
Alzheimer    O
's    O
disease    O
;    O
(    O
c    O
)    O
"    O
infective    O
organism    O
"    O
,    O
e.g.    O
Tuberculosis    O
,    O
Measles    O
;    O
(    O
d    O
)    O
"    O
physiologically    O
"    O
,    O
e.g.    O
myasthenia    O
gravis    O
;    O
(    O
e    O
)    O
"    O
biochemically    O
"    O
,    O
e.g.    O
aminoaciduria    O
;    O
(    O
e    O
)    O
"    O
chromosomally    O
"    O
,    O
e.g.    O
trisomy    O
21    O
,    O
Turner    O
's    O
syndrome    O
;    O
(    O
f    O
)    O
"    O
molecularly    O
"    O
,    O
e.g.    O
thalassemia    O
;    O
(    O
g    O
)    O
"    O
genetically    O
"    O
,    O
e.g.    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
cystic    O
fibrosis    O
;    O
and    O
(    O
h    O
)    O
"    O
syndrome    O
"    O
,    O
e.g.    O
migraine    O
,    O
torticollis    O
,    O
essential    O
tremor    O
,    O
blepharospasm    O
,    O
torsion    O
dystonia    O
and    O
most    O
(    O
so    O
-    O
called    O
)    O
mental    O
disorders    O
.    O

The    O
diabetic    O
,    O
pancreatic    O
,    O
and    O
neuroprotection    O
implications    O
of    O
GLP1R    O
are    O
also    O
thought    O
to    O
be    O
potential    O
therapies    O
for    O
treating    O
the    O
diabetes    O
and    O
energy    O
metabolism    O
abnormalities    O
associated    O
with    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
affecting    O
the    O
brain    O
and    O
periphery    O
.    O

Genetics    O
had    O
been    O
used    O
in    O
diseases    O
with    O
a    O
single    O
genetic    O
tie    O
,    O
such    O
as    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
cystic    O
fibrosis    O
,    O
and    O
sickle    O
-    O
cell    O
anemia    O
,    O
but    O
researchers    O
were    O
skeptical    O
about    O
the    O
use    O
of    O
genetics    O
in    O
the    O
more    O
common    O
diseases    O
caused    O
by    O
multiple    O
genetic    O
factors    O
as    O
well    O
as    O
environmental    O
influences    O
.    O

Glutamate    O
is    O
the    O
main    O
excitatory    O
neurotransmitter    O
in    O
the    O
mammalian    O
brain    O
and    O
has    O
been    O
implicated    O
in    O
mediating    O
neurological    O
disorders    O
such    O
as    O
epilepsy    O
and    O
neurodegenerative    O
diseases    O
such    O
as    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

Jakob    O
disease    O
,    O
dementia    O
(    O
and    O
dementias    O
such    O
as    O
Alzheimer    O
's    O
disease    O
,    O
vascular    O
dementia    O
,    O
and    O
frontotemporal    O
dementia    O
)    O
,    O
Korsakoff    O
's    O
syndrome    O
,    O
excessive    O
vitamin    O
D    O
,    O
hypothyroidism    O
,    O
hyperthyroidism    O
,    O
general    O
fatigue    O
,    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
Pick    O
's    O
disease    O
,    O
progressive    O
supranuclear    O
palsy    O
(    O
PSP    O
)    O
,    O
brain    O
damage    O
,    O
schizophrenia    O
,    O
schizoid    O
personality    O
disorder    O
,    O
bipolar    O
disorder    O
,    O
autism    O
,    O
ADHD    O
,    O
Asperger    O
's    O
syndrome    O
,    O
and    O
others    O
.    O

Over    O
the    O
last    O
20    O
years    O
,    O
these    O
tests    O
have    O
gone    O
on    O
to    O
be    O
used    O
in    O
more    O
than    O
600    O
published    O
studies    O
of    O
Parkinson    O
's    O
disease    O
,    O
Alzheimer    O
's    O
disease    O
,    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
Depression    O
,    O
Schizophrenia    O
,    O
Autism    O
,    O
Obsessive    O
-    O
Compulsive    O
Disorder    O
and    O
ADHD    O
,    O
among    O
others    O
.    O

Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025

Latrepirdine    O
failed    O
in    O
the    O
phase    O
III    O
trial    O
for    O
Huntington    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

Latrepirdine    O
is    O
an    O
orally    O
active    O
,    O
small    O
molecule    O
compound    O
that    O
has    O
been    O
shown    O
to    O
inhibit    O
brain    O
cell    O
death    O
in    O
animal    O
models    O
of    O
Alzheimer    O
's    O
disease    O
and    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

Woody    O
Guthrie    O
,    O
55    O
,    O
American    O
folk    O
singer    O
and    O
songwriter    O
,    O
died    O
of    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025

The    O
non    O
-    O
deuterated    O
version    O
of    O
tetrabenazine    O
is    O
an    O
approved    O
drug    O
for    O
the    O
involuntary    O
movements    O
in    O
Huntington’s    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
however    O
its    O
short    O
half    O
-    O
life    O
limits    O
its    O
clinical    O
efficacy    O
.    O

It    O
may    O
have    O
use    O
for    O
treatments    O
of    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
Parkinson    O
disease    O
,    O
tauopathies    O
or    O
Batten    O
disease    O
,    O
as    O
it    O
may    O
correct    O
defects    O
in    O
autophagy    O
seen    O
in    O
these    O
diseases    O
and    O
improve    O
removal    O
of    O
aggregated    O
proteins    O
and    O
other    O
aberrant    O
storage    O
material    O
.    O

The    O
Inheritance    O
is    O
a    O
2014    O
documentary    O
feature    O
film    O
about    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
written    O
by    O
Bridget    O
Lyon    O
and    O
directed    O
by    O
Jeffrey    O
McDonald    O
.    O

Cystamine    O
has    O
also    O
been    O
studied    O
as    O
a    O
potential    O
medicinal    O
compound    O
in    O
the    O
case    O
of    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
Alzheimer    O
's    O
disease    O
and    O
carbon    O
tetrachloride    O
liver    O
damage    O

Diseases    O
amenable    O
to    O
UPR    O
inhibition    O
include    O
Creutzfeldt    O
–    O
Jakob    O
disease    O
,    O
Alzheimer    O
's    O
disease    O
,    O
Parkinson    O
's    O
disease    O
,    O
and    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

Matrix    O
families    O
of    O
interest    O
include    O
the    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
gene    O
regulatory    O
region    O
,    O
nerve    O
growth    O
factor    O
,    O
nuclear    O
respiratory    O
factor    O
,    O
pleomorphic    O
adenoma    O
gene    O
,    O
zinc    O
finger    O
transcription    O
factors    O
,    O
and    O
an    O
E2F    O
-    O
myc    O
activator    O
/    O
cell    O
cycle    O
regulator    O
.    O

It    O
is    O
also    O
related    O
to    O
other    O
neurodegenerative    O
diseases    O
caused    O
by    O
similar    O
mutations    O
,    O
such    O
as    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

Spinal    O
and    O
bulbar    O
muscular    O
atrophy    O
may    O
share    O
mechanistic    O
features    O
with    O
other    O
disorders    O
caused    O
by    O
polyglutamine    O
expansion    O
,    O
such    O
as    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

The    O
other    O
category    O
of    O
movement    O
disorder    O
resulting    O
from    O
damage    O
to    O
the    O
basal    O
ganglia    O
,    O
hyperkinesia    O
,    O
features    O
an    O
exaggeration    O
of    O
unwanted    O
motion    O
,    O
like    O
twitching    O
or    O
writhing    O
in    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
or    O
Tourette    O
syndrome    O
.    O

Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025

This    O
enzyme    O
participates    O
in    O
complement    O
and    O
coagulation    O
cascades    O
and    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

CHDI    O
Foundation    O
,    O
a    O
US    O
non    O
-    O
profit    O
foundation    O
that    O
aims    O
to    O
develop    O
treatments    O
for    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025

Major    O
diseases    O
being    O
modelized    O
with    O
PSCs    O
-    O
derived    O
cells    O
are    O
amyotrophic    O
lateral    O
sclerosis    O
(    O
ALS    O
)    O
,    O
Alzheimer    O
's    O
(    O
AD    O
)    O
,    O
Parkinson    O
's    O
(    O
PD    O
)    O
,    O
fragile    O
X    O
syndrome    O
(    O
FXS    O
)    O
,    O
Huntington    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
(    O
HD    O
)    O
,    O
Down    O
syndrome    O
,    O
Spinal    O
muscular    O
atrophy    O
(    O
SMA    O
)    O
,    O
muscular    O
dystrophies    O
,    O
cystic    O
fibrosis    O
,    O
Long    O
QT    O
syndrome    O
,    O
and    O
Type    O
I    O
diabetes    O
.    O

Likewise    O
,    O
diseases    O
commonly    O
associated    O
with    O
motor    O
deficits    O
,    O
such    O
as    O
Huntington's    B-AutosomalDominantDisease114162025
and    O
Parkinson    O
's    O
disease    O
,    O
have    O
a    O
wide    O
variety    O
of    O
symptoms    O
and    O
associated    O
brain    O
damage    O
that    O
make    O
it    O
impossible    O
to    O
pinpoint    O
whether    O
or    O
not    O
motor    O
memory    O
is    O
in    O
fact    O
impaired    O
.    O

The    O
company    O
targets    O
genetic    O
disorders    O
with    O
a    O
large    O
unmet    O
medical    O
need    O
,    O
with    O
a    O
primary    O
focus    O
on    O
neuromuscular    O
and    O
neurodegenerative    O
disorders    O
such    O
as    O
Duchenne    O
Muscular    O
Dystrophy    O
(    O
DMD    O
)    O
,    O
Myotonic    O
Dystrophy    O
and    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

RFLP    O
also    O
aids    O
in    O
the    O
identification    O
of    O
the    O
Huntingtin    O
(    O
HTT    O
)    O
gene    O
which    O
is    O
predictive    O
of    O
an    O
adult    O
-    O
onset    O
autosomal    O
disorder    O
called    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
(    O
HD    O
)    O
.    O

His    O
mother    O
suffered    O
from    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

Excitotoxicity    O
may    O
be    O
involved    O
in    O
spinal    O
cord    O
injury    O
,    O
stroke    O
,    O
traumatic    O
brain    O
injury    O
,    O
hearing    O
loss    O
(    O
through    O
noise    O
overexposure    O
or    O
ototoxicity    O
)    O
,    O
and    O
in    O
neurodegenerative    O
diseases    O
of    O
the    O
central    O
nervous    O
system    O
(    O
CNS    O
)    O
such    O
as    O
multiple    O
sclerosis    O
,    O
Alzheimer    O
's    O
disease    O
,    O
amyotrophic    O
lateral    O
sclerosis    O
(    O
ALS    O
)    O
,    O
Parkinson    O
's    O
disease    O
,    O
alcoholism    O
or    O
alcohol    O
withdrawal    O
and    O
especially    O
over    O
-    O
rapid    O
benzodiazepine    O
withdrawal    O
,    O
and    O
also    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

By    O
1956    O
,    O
Guthrie    O
was    O
hospitalized    O
with    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
a    O
hereditary    O
condition    O
.    O

Thirteen    O
says    O
that    O
it    O
was    O
Huntington's    B-AutosomalDominantDisease114162025
chorea    I-AutosomalDominantDisease114162025
,    O
meaning    O
that    O
she    O
has    O
a    O
50%    O
chance    O
of    O
also    O
carrying    O
the    O
mutation    O
that    O
leads    O
to    O
the    O
disease    O
,    O
which    O
is    O
what    O
caused    O
her    O
to    O
become    O
upset    O
when    O
she    O
dropped    O
her    O
files    O
and    O
when    O
her    O
hand    O
shook    O
.    O

If    O
she    O
has    O
inherited    O
Huntington's    B-AutosomalDominantDisease114162025
chorea    I-AutosomalDominantDisease114162025
,    O
then    O
she    O
has    O
about    O
twelve    O
years    O
to    O
live    O
.    O

Other    O
disorders    O
,    O
such    O
as    O
Huntington    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
occur    O
when    O
an    O
individual    O
inherits    O
only    O
one    O
dominant    O
allele    O
.    O

Hyperkinesia    O
is    O
a    O
state    O
of    O
excessive    O
restlessness    O
which    O
is    O
featured    O
in    O
a    O
large    O
variety    O
of    O
disorders    O
that    O
affect    O
the    O
ability    O
to    O
control    O
motor    O
movement    O
,    O
such    O
as    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

Chorea    O
is    O
also    O
the    O
prominent    O
movement    O
featured    O
in    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

Hyperkinesia    O
,    O
more    O
specifically    O
chorea    O
,    O
is    O
the    O
hallmark    O
symptom    O
of    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
formerly    O
referred    O
to    O
as    O
"    O
Huntington    O
’s    O
chorea    O
"    O
.    O

It    O
helps    O
that    O
Mark    O
's    O
doctor    O
-    O
father    O
,    O
Albert    O
Rua    O
(    O
Giannini    O
)    O
has    O
furnished    O
them    O
with    O
their    O
residence    O
and    O
is    O
nearby    O
,    O
especially    O
when    O
Mark    O
begins    O
to    O
suffer    O
from    O
seizures    O
again    O
due    O
to    O
the    O
progression    O
of    O
his    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
which    O
also    O
causes    O
him    O
to    O
become    O
increasingly    O
mentally    O
unstable    O
.    O

hairpin    O
-    O
haploid    O
-    O
haploinsufficiency    O
-    O
helix    O
-    O
loop    O
-    O
helix    O
-    O
hematopoietic    O
stem    O
cell    O
-    O
hemophilia    O
-    O
heteroduplex    O
DNA    O
-    O
heterozygous    O
-    O
highly    O
conserved    O
sequence    O
-    O
Hirschsprung    O
's    O
disease    O
-    O
histone    O
-    O
hnRNA    O
-    O
holoprosencephaly    O
-    O
homologous    O
recombination    O
-    O
homology    O
-    O
homozygous    O
-    O
host    O
strain    O
(    O
bacterial    O
)    O
-    O
human    O
artificial    O
chromosome    O
-    O
Human    O
Genome    O
Project    O
-    O
human    O
immunodeficiency    O
virus    O
-    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
-    O
hybridization    O
-    O
hybridoma    O
-    O
hydrophilicity    O
plot    O
-    O

Dementia    O
due    O
to    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025

Neurogenesis    O
in    O
the    O
adult    O
brain    O
is    O
often    O
associated    O
with    O
diseases    O
that    O
deteriorate    O
the    O
CNS    O
,    O
like    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
Alzheimer    O
's    O
disease    O
,    O
and    O
Parkinson    O
's    O
disease    O
.    O

Some    O
examples    O
of    O
central    O
disorders    O
include    O
cerebrovascular    O
accident    O
,    O
Parkinson    O
's    O
disease    O
,    O
multiple    O
sclerosis    O
,    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
and    O
Creutzfeldt    O
–    O
Jakob    O
disease    O
.    O

Other    O
effects    O
of    O
the    O
disease    O
may    O
include    O
epilepsy    O
,    O
behaviour    O
changes    O
,    O
muscle    O
degeneration    O
,    O
and    O
neuronal    O
degradation    O
similar    O
to    O
Huntington's    B-AutosomalDominantDisease114162025
Disease    I-AutosomalDominantDisease114162025
.    O

Recent    O
research    O
indicates    O
that    O
sufferers    O
from    O
neurological    O
diseases    O
like    O
Huntington    B-AutosomalDominantDisease114162025
's    O
and    O
Parkinson    O
's    O
may    O
have    O
unusually    O
high    O
levels    O
of    O
one    O
type    O
of    O
transglutaminase    O
,    O
tissue    O
transglutaminase    O
.    O

Lacosamide    O
and    O
other    O
AEDs    O
have    O
been    O
used    O
off    O
-    O
label    O
in    O
the    O
management    O
of    O
bipolar    O
disorder    O
,    O
cocaine    O
addiction    O
,    O
dementia    O
,    O
depression    O
,    O
diabetic    O
peripheral    O
neuropathy    O
,    O
fibromyalgia    O
,    O
headache    O
,    O
hiccoughs    O
,    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
mania    O
,    O
migraine    O
,    O
obsessive    O
-    O
compulsive    O
disorder    O
,    O
panic    O
disorder    O
,    O
restless    O
leg    O
syndrome    O
,    O
and    O
tinnitus    O
.    O

Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025

CBG    O
has    O
been    O
shown    O
to    O
have    O
neuroprotective    O
properties    O
and    O
may    O
prove    O
promising    O
for    O
the    O
treatment    O
of    O
neurodegenerative    O
diseases    O
such    O
as    O
Huntington’s    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
and    O
multiple    O
sclerosis    O
.    O

23    O
May    O
–    O
Very    O
early    O
symptoms    O
of    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
such    O
as    O
depression    O
and    O
anxiety    O
,    O
can    O
be    O
prevented    O
in    O
mice    O
by    O
switching    O
off    O
a    O
protein    O
,    O
according    O
to    O
a    O
new    O
study    O
.    O

For    O
example    O
,    O
the    O
genetic    O
disorder    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
is    O
diagnosed    O
when    O
symptoms    O
appear    O
at    O
around    O
50    O
,    O
and    O
the    O
person    O
dies    O
at    O
around    O
65    O
.    O

Dowell    O
and    O
his    O
family    O
have    O
worked    O
to    O
raise    O
awareness    O
and    O
find    O
a    O
cure    O
for    O
Huntington's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
a    O
disease    O
which    O
has    O
afflicted    O
his    O
brother    O
and    O
his    O
father    O
.    O

Congenital    B-AutosomalDominantDisease114162025
stromal    I-AutosomalDominantDisease114162025
corneal    I-AutosomalDominantDisease114162025
dystrophy    I-AutosomalDominantDisease114162025

=    O
=    O
Dundar    B-AutosomalDominantDisease114162025
Acropectoral    I-AutosomalDominantDisease114162025
Syndrome    I-AutosomalDominantDisease114162025

Hypoalphalipoproteinaemia    B-AutosomalDominantDisease114162025

Neurogenic    O
orthostatic    O
hypotension    O
(    O
NOH    O
)    O
dopamine    O
beta    O
hydrolase    O
deficiency    O
,    O
as    O
well    O
as    O
NOH    O
associated    O
with    O
multiple    O
system    O
atrophy    O
(    O
MSA    O
)    O
,    O
familial    B-AutosomalDominantDisease114162025
amyloid    I-AutosomalDominantDisease114162025
polyneuropathy    I-AutosomalDominantDisease114162025
(    O
FAP    O
)    O
,    O
pure    O
autonomic    O
failure    O
(    O
PAF    O
)    O
.    O

TTR    O
misfolding    O
and    O
aggregation    O
is    O
known    O
to    O
be    O
associated    O
with    O
the    O
amyloid    O
diseases    O
senile    O
systemic    O
amyloidosis    O
(    O
SSA    O
)    O
,    O
familial    B-AutosomalDominantDisease114162025
amyloid    I-AutosomalDominantDisease114162025
polyneuropathy    I-AutosomalDominantDisease114162025
(    O
FAP    O
)    O
,    O
and    O
familial    O
amyloid    O
cardiomyopathy    O
(    O
FAC    O
)    O
.    O

Currently    O
,    O
the    O
main    O
target    O
diseases    O
being    O
studied    O
are    O
familial    B-AutosomalDominantDisease114162025
amyloid    I-AutosomalDominantDisease114162025
polyneuropathy    I-AutosomalDominantDisease114162025
(    O
FAP    O
)    O
and    O
Alzheimer    O
's    O
disease    O
.    O

Onychauxis    O
presents    O
with    O
thickened    O
nails    O
without    O
deformity    O
,    O
and    O
this    O
simple    O
thickening    O
may    O
be    O
the    O
result    O
of    O
trauma    O
,    O
acromegaly    O
,    O
Darier's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
psoriasis    O
,    O
or    O
pityriasis    O
rubra    O
pilaris    O
,    O
or    O
,    O
in    O
some    O
cases    O
,    O
hereditary    O
.    O

"    O
Demonstration    O
von    O
Psorospermien    O
der    O
Darierschen    O
Dermatose    O
"    O
,    O
1896    O
–    O
Demonstration    O
of    O
Psorospermia    O
in    O
regards    O
to    O
Darier's    B-AutosomalDominantDisease114162025
dermatosis    I-AutosomalDominantDisease114162025
.    O

In    O
1999    O
Sakuntabhai    O
discovered    O
a    O
gene    O
responsible    O
for    O
Darrier    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
a    O
monogenic    O
skin    O
disorder    O
.    O

Zimmermann–Laband    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Larsen    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Larsen    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Reis-Bucklers    B-AutosomalDominantDisease114162025
corneal    I-AutosomalDominantDisease114162025
dystrophy    I-AutosomalDominantDisease114162025

A    O
glucose    O
level    O
of    O
less    O
than    O
one    O
third    O
of    O
blood    O
glucose    O
levels    O
in    O
association    O
with    O
low    O
CSF    O
lactate    O
levels    O
is    O
typical    O
in    O
hereditary    O
CSF    O
glucose    O
transporter    O
deficiency    O
also    O
known    O
as    O
De    B-AutosomalDominantDisease114162025
Vivo    I-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

Keratolytic    B-AutosomalDominantDisease114162025
winter    I-AutosomalDominantDisease114162025
erythema    I-AutosomalDominantDisease114162025

A    O
lyophilised    O
form    O
of    O
hemin    O
is    O
used    O
as    O
a    O
pharmacological    O
agent    O
in    O
certain    O
cases    O
for    O
the    O
treatment    O
of    O
porphyria    O
attacks    O
,    O
particularly    O
in    O
acute    B-AutosomalDominantDisease114162025
intermittent    I-AutosomalDominantDisease114162025
porphyria    I-AutosomalDominantDisease114162025
.    O

Acute    B-AutosomalDominantDisease114162025
intermittent    I-AutosomalDominantDisease114162025
porphyria    I-AutosomalDominantDisease114162025

The    O
patient    O
's    O
underlying    O
condition    O
was    O
probably    O
acute    B-AutosomalDominantDisease114162025
intermittent    I-AutosomalDominantDisease114162025
porphyria    I-AutosomalDominantDisease114162025
,    O
which    O
can    O
be    O
provoked    O
by    O
medicines    O
.    O

During    O
the    O
season    O
,    O
House    O
tries    O
to    O
cope    O
with    O
his    O
feelings    O
for    O
his    O
ex    O
-    O
girlfriend    O
Stacy    O
Warner    O
,    O
who    O
,    O
after    O
House    O
diagnosed    O
her    O
husband    O
with    O
acute    B-AutosomalDominantDisease114162025
intermittent    I-AutosomalDominantDisease114162025
porphyria    I-AutosomalDominantDisease114162025
,    O
has    O
taken    O
a    O
job    O
in    O
the    O
legal    O
department    O
of    O
Princeton    O
-    O
Plainsboro    O
Teaching    O
Hospital    O
.    O

These    O
include    O
epilepsy    O
,    O
bipolar    O
disorder    O
,    O
sunstroke    O
,    O
acute    B-AutosomalDominantDisease114162025
intermittent    I-AutosomalDominantDisease114162025
porphyria    I-AutosomalDominantDisease114162025
,    O
lead    O
poisoning    O
,    O
and    O
Ménière    O
's    O
disease    O
.    O

Arnold    O
and    O
Loftus    O
put    O
forward    O
the    O
diagnosis    O
of    O
Acute    B-AutosomalDominantDisease114162025
Intermittent    I-AutosomalDominantDisease114162025
Porphyria    I-AutosomalDominantDisease114162025
(    O
often    O
referred    O
to    O
as    O
simply    O
"    O
AIP    O
"    O
)    O
.    O

Albright's    B-AutosomalDominantDisease114162025
hereditary    I-AutosomalDominantDisease114162025
osteodystrophy    I-AutosomalDominantDisease114162025

Albright's    B-AutosomalDominantDisease114162025
hereditary    I-AutosomalDominantDisease114162025
osteodystrophy    I-AutosomalDominantDisease114162025
is    O
a    O
form    O
of    O
osteodystrophy    O
,    O
and    O
is    O
classified    O
as    O
the    O
phenotype    O
of    O
pseudohypoparathyroidism    O
type    O
1A    O
;    O
this    O
is    O
a    O
condition    O
in    O
which    O
the    O
body    O
does    O
not    O
respond    O
to    O
parathyroid    O
hormone    O
.    O

They    O
are    O
also    O
seen    O
in    O
Gardner's    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
and    O
Nevoid    O
Basal    O
Cell    O
Carcinoma    O
Syndrome    O
on    O
the    O
head    O
and    O
neck    O
.    O

The    O
combination    O
of    O
polyposis    O
,    O
osteomas    O
,    O
fibromas    O
and    O
sebaceous    O
cysts    O
is    O
termed    O
'    O
'    O
Gardner's    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
"    O
(    O
with    O
or    O
without    O
abnormal    O
scarring    O
)    O
.    O

Gardner    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
also    O
known    O
as    O
Gardner's    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
or    O
familial    B-AutosomalDominantDisease114162025
colorectal    I-AutosomalDominantDisease114162025
polyposis    I-AutosomalDominantDisease114162025
,    O
is    O
an    O
autosomal    O
dominant    O
form    O
of    O
polyposis    O
characterized    O
by    O
the    O
presence    O
of    O
multiple    O
polyps    O
in    O
the    O
colon    O
together    O
with    O
tumors    O
outside    O
the    O
colon    O
.    O

Gardner's    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
can    O
be    O
associated    O
with    O
failure    O
of    O
tooth    O
eruption    O
,    O
supernumerary    O
teeth    O
,    O
and    O
dentigerous    O
cysts    O
.    O

A    O
few    O
common    O
examples    O
are    O
:    O
Prader    O
-    O
Willi    O
syndrome    O
,    O
Bardet    O
-    O
Biedl    O
syndrome    O
,    O
Cohen    O
syndrome    O
,    O
and    O
MOMO    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Patients    O
with    O
the    O
acute    O
porphyrias    O
(    O
AIP    B-AutosomalDominantDisease114162025
,    O
HCP    O
,    O
VP    B-AutosomalDominantDisease114162025
)    O
are    O
at    O
increased    O
risk    O
over    O
their    O
life    O
for    O
hepatocellular    O
carcinoma    O
(    O
primary    O
liver    O
cancer    O
)    O
and    O
may    O
require    O
monitoring    O
.    O

As    O
in    O
other    O
cases    O
where    O
the    O
establishment    O
of    O
a    O
population    O
group    O
has    O
been    O
propagated    O
by    O
many    O
of    O
the    O
same    O
progenitors    O
and    O
their    O
children    O
,    O
Afrikaners    O
have    O
also    O
experienced    O
a    O
dramatic    O
increase    O
in    O
the    O
frequency    O
of    O
some    O
otherwise    O
rare    O
deleterious    O
ailments    O
,    O
including    O
"    O
Variegate    B-AutosomalDominantDisease114162025
porphyria    I-AutosomalDominantDisease114162025
"    O
.    O

Variegate    B-AutosomalDominantDisease114162025
porphyria    I-AutosomalDominantDisease114162025
(    O
ILDS    O
E80.230    O
)    O

In    O
1988    O
,    O
an    O
American    O
woman    O
who    O
had    O
married    O
a    O
Shark    O
Bay    O
Aboriginal    O
man    O
contacted    O
Dr    O
Playford    O
and    O
described    O
how    O
her    O
husband    O
had    O
died    O
some    O
years    O
before    O
from    O
a    O
disease    O
called    O
variegate    B-AutosomalDominantDisease114162025
porphyria    I-AutosomalDominantDisease114162025
.    O

Feingold    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
(    O
also    O
called    O
oculodigitoesophagoduodenal    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
)    O
is    O
a    O
rare    O
autosomal    O
dominant    O
hereditary    O
disorder    O
.    O

Hawkinsinuria    B-AutosomalDominantDisease114162025
,    O
also    O
called    O
4-Alpha-hydroxyphenylpyruvate    B-AutosomalDominantDisease114162025
hydroxylase    I-AutosomalDominantDisease114162025
deficiency    I-AutosomalDominantDisease114162025
,    O
is    O
an    O
autosomal    O
dominant    O
metabolic    O
disorder    O
affecting    O
the    O
metabolism    O
of    O
tyrosine    O
.    O

Mutations    O
in    O
this    O
gene    O
cause    O
various    O
glaucoma    O
phenotypes    O
including    O
primary    O
congenital    O
glaucoma    O
,    O
autosomal    O
dominant    O
iridogoniodysgenesis    O
anomaly    O
,    O
and    O
Axenfeld-Rieger    B-AutosomalDominantDisease114162025
anomaly    I-AutosomalDominantDisease114162025
.    O

Congenital    B-AutosomalDominantDisease114162025
distal    I-AutosomalDominantDisease114162025
spinal    I-AutosomalDominantDisease114162025
muscular    I-AutosomalDominantDisease114162025
atrophy    I-AutosomalDominantDisease114162025
(    O
congenital    O
dSMA    O
)    O
is    O
a    O
hereditary    O
genetic    O
condition    O
characterized    O
by    O
muscle    O
wasting    O
(    O
atrophy    O
)    O
,    O
particularly    O
of    O
distal    O
muscles    O
in    O
legs    O
and    O
hands    O
,    O
and    O
by    O
early    O
-    O
onset    O
contractures    O
(    O
permanent    O
shortening    O
of    O
a    O
muscle    O
or    O
joint    O
)    O
of    O
the    O
hip    O
,    O
knee    O
,    O
and    O
ankle    O
.    O

Keratin    O
6B    O
has    O
been    O
associated    O
with    O
the    O
PC2    O
variant    O
of    O
pachyonychia    B-AutosomalDominantDisease114162025
congenita    I-AutosomalDominantDisease114162025
where    O
affected    O
individuals    O
may    O
develop    O
more    O
skin    O
cysts    O
than    O
the    O
PC1    O
type    O
.    O

This    O
has    O
been    O
identified    O
as    O
a    O
form    O
of    O
Pachyonychia    B-AutosomalDominantDisease114162025
congenita    I-AutosomalDominantDisease114162025
.    O

Pachyonychia    B-AutosomalDominantDisease114162025
congenita    I-AutosomalDominantDisease114162025

Wallis–Zieff–Goldblatt    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Roussy–Lévy    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Mutations    O
in    O
this    O
gene    O
have    O
been    O
shown    O
to    O
cause    O
dominant    O
axonal    O
Charcot    O
-    O
Marie    O
-    O
Tooth    O
disease    O
as    O
well    O
as    O
spinal    B-AutosomalDominantDisease114162025
muscular    I-AutosomalDominantDisease114162025
atrophy    I-AutosomalDominantDisease114162025
with    I-AutosomalDominantDisease114162025
lower    I-AutosomalDominantDisease114162025
extremity    I-AutosomalDominantDisease114162025
predominance    I-AutosomalDominantDisease114162025
(    O
SMA    O
-    O
LED    O
)    O
.    O

Popliteal    B-AutosomalDominantDisease114162025
pterygium    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
an    O
inherited    O
condition    O
affecting    O
the    O
face    O
,    O
limbs    O
,    O
and    O
genitalia    O

The    O
clinical    O
signs    O
seen    O
in    O
VWS    O
are    O
similar    O
to    O
those    O
of    O
popliteal    B-AutosomalDominantDisease114162025
pterygium    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
(    O
PPS    O
)    O
,    O
which    O
is    O
also    O
an    O
autosomal    O
dominant    O
disease    O
.    O

Hereditary    B-AutosomalDominantDisease114162025
mucoepithelial    I-AutosomalDominantDisease114162025
dysplasia    I-AutosomalDominantDisease114162025
(    O
HMD    O
)    O
,    O
or    O
simply    O
mucoepithelial    B-AutosomalDominantDisease114162025
dysplasia    I-AutosomalDominantDisease114162025
,    O
is    O
a    O
rare    O
autosomal    O
dominant    O
multiepithelial    O
disorder    O
causing    O
systemic    O
maldevelopment    O
of    O
the    O
epithelia    O
and    O
mucous    O
membranes    O
that    O
line    O
the    O
surface    O
of    O
tissues    O
and    O
structures    O
throughout    O
the    O
body    O
,    O
particularly    O
affecting    O
systems    O
affiliated    O
with    O
mucosa    O
,    O
which    O
includes    O
the    O
respiratory    O
,    O
digestive    O
,    O
urinary    O
,    O
reproductive    O
and    O
immune    O
systems    O
.    O

Cryoglobulonemic    O
disease    O
must    O
also    O
be    O
distinguished    O
from    O
frostbite    O
as    O
well    O
as    O
numerous    O
other    O
conditions    O
that    O
have    O
a    O
clinical    O
(    O
particularly    O
cutaneous    O
)    O
presentation    O
similar    O
to    O
cryoglobulinemic    O
disease    O
but    O
are    O
not    O
exacerbated    O
by    O
cold    O
temperature    O
,    O
e.g.    O
dysfibrinogenemia    B-AutosomalDominantDisease114162025
and    O
dysfibrinogenemic    O
disease    O
(    O
conditions    O
involving    O
the    O
intravascular    O
deposition    O
of    O
genetically    O
abnormal    O
circulating    O
fibrinogens    O
)    O
,    O
purpura    O
fulminans    O
,    O
cholesterol    O
emboli    O
,    O
warfarin    O
necrosis    O
,    O
ecthyma    O
gangrenosum    O
,    O
and    O
various    O
hypercoagulable    O
states    O
.    O

Dysfibrinogenemia    B-AutosomalDominantDisease114162025

Holt-Oram    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Holt–Oram    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Holt–Oram    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
has    O
an    O
autosomal    O
dominant    O
pattern    O
of    O
inheritance    O
.    O

Gillespie    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
also    O
called    O
aniridia,    B-AutosomalDominantDisease114162025
cerebellar    I-AutosomalDominantDisease114162025
ataxia    I-AutosomalDominantDisease114162025
and    I-AutosomalDominantDisease114162025
mental    I-AutosomalDominantDisease114162025
deficiency.    I-AutosomalDominantDisease114162025
is    O
a    O
rare    O
genetic    O
disorder    O
.    O

Examples    O
of    O
autism    O
that    O
has    O
arisen    O
from    O
a    O
rare    O
or    O
de    O
novo    O
mutation    O
in    O
a    O
single    O
-    O
gene    O
or    O
locus    O
include    O
the    O
neurodevelopmental    O
disorders    O
fragile    O
X    O
syndrome    O
,    O
22q13    B-AutosomalDominantDisease114162025
deletion    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
and    O
16p11.2    O
deletion    O
syndrome    O
.    O

Behavior    O
is    O
described    O
as    O
"    O
autistic    O
-    O
like    O
"    O
and    O
includes    O
high    O
tolerance    O
to    O
pain    O
and    O
habitual    O
chewing    O
or    O
mouthing    O
(    O
see    O
also    O
22q13    B-AutosomalDominantDisease114162025
deletion    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
)    O
.    O

Beaded    B-AutosomalDominantDisease114162025
hair    I-AutosomalDominantDisease114162025

Monilethrix    B-AutosomalDominantDisease114162025

Giant    O
platelet    O
disorder    O
occurs    O
for    O
inherited    O
diseases    O
like    O
Bernard    O
-    O
Soulier    O
syndrome    O
,    O
gray    B-AutosomalDominantDisease114162025
platelet    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
and    O
May    O
-    O
Hegglin    O
anomaly    O
.    O

Caused    O
by    O
alpha    O
granules    O
defect    O
:    O
Gray    B-AutosomalDominantDisease114162025
platelet    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Peutz-Jeghers    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
—    O
an    O
autosomal    O
dominant    O
disorder    O
characterized    O
by    O
hyperpigmented    O
macules    O
on    O
the    O
lips    O
and    O
oral    O
mucosa    O
and    O
gastrointestinal    O
polyps    O
.    O

Peutz-Jeghers    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

"    O
Peutz-Jeghers    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
"    O
is    O
associated    O
with    O
polyps    O
of    O
the    O
GI    O
tract    O
and    O
also    O
increased    O
pigmentation    O
around    O
the    O
lips    O
,    O
genitalia    O
,    O
buccal    O
mucosa    O
feet    O
and    O
hands    O
.    O

File    O
:    O
Peutz    O
-    O
Jeghers    O
syndrome    O
polyp.jpg|Micrograph    O
of    O
a    O
Peutz-Jeghers    B-AutosomalDominantDisease114162025
colonic    I-AutosomalDominantDisease114162025
polyp    I-AutosomalDominantDisease114162025
-    O
a    O
type    O
of    O
hamartomatous    O
polyp    O
.    O
H&E    O
stain    O
.    O

Peutz–Jeghers    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
can    O
cause    O
dark    O
spots    O
on    O
the    O
oral    O
mucosa    O
or    O
on    O
the    O
lips    O
or    O
the    O
skin    O
around    O
the    O
mouth    O
.    O

Medullary    B-AutosomalDominantDisease114162025
cystic    I-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025

There    O
are    O
no    O
tests    O
for    O
Stickler    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
or    O
Marshall    O
syndrome    O
.    O

Haberman    O
's    O
daughter    O
was    O
born    O
in    O
1980    O
with    O
Stickler    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
a    O
congenital    O
abnormality    O
that    O
included    O
a    O
cleft    O
palate    O
.    O

Stickler    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
:    O
Several    O
of    O
the    O
mutations    O
in    O
the    O
COL2A1    O
gene    O
result    O
in    O
the    O
production    O
of    O
an    O
abnormally    O
short    O
protein    O
that    O
can    O
not    O
be    O
incorporated    O
into    O
a    O
type    O
II    O
collagen    O
fiber    O
.    O

Hypermobility    O
may    O
be    O
symptomatic    O
of    O
a    O
serious    O
medical    O
condition    O
,    O
such    O
as    O
Stickler    B-AutosomalDominantDisease114162025
Syndrome    I-AutosomalDominantDisease114162025
,    O
Ehlers    O
-    O
Danlos    O
syndrome    O
,    O
Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
Loeys    O
-    O
Dietz    O
syndrome    O
,    O
rheumatoid    O
arthritis    O
,    O
osteogenesis    O
imperfecta    O
,    O
lupus    O
,    O
polio    O
,    O
Down    O
syndrome    O
,    O
morquio    O
syndrome    O
,    O
cleidocranial    O
dysostosis    O
or    O
myotonia    O
congenita    O
.    O

Jackson–Weiss    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

She    O
discovered    O
that    O
similar    O
mutations    O
in    O
the    O
same    O
gene    O
,    O
fibroblast    O
growth    O
factor    O
receptor    O
2    O
or    O
FGFR2    O
,    O
cause    O
both    O
Jackson–Weiss    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
and    O
Crouzon    O
syndrome    O
.    O

Moreover    O
,    O
the    O
combination    O
is    O
effective    O
in    O
gonadotropin    O
-    O
independent    O
precocious    O
puberty    O
,    O
namely    O
familial    B-AutosomalDominantDisease114162025
male-limited    I-AutosomalDominantDisease114162025
precocious    I-AutosomalDominantDisease114162025
puberty    I-AutosomalDominantDisease114162025
(    O
also    O
known    O
as    O
testotoxicosis    O
)    O
,    O
where    O
analogues    O
notably    O
are    O
not    O
effective    O
.    O

Defects    O
are    O
associated    O
with    O
Bethlem    B-AutosomalDominantDisease114162025
myopathy    I-AutosomalDominantDisease114162025
and    O
Ullrich    O
congenital    O
muscular    O
dystrophy    O
.    O

Tricho    O
–    O
rhino    O
–    O
phalangeal    O
syndrome    O
type    O
2    O
(    O
also    O
known    O
as    O
Langer-Giedion    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
)    O
is    O
a    O
genetic    O
disorder    O
consisting    O
of    O
fine    O
and    O
sparse    O
scalp    O
hair    O
,    O
thin    O
nails    O
,    O
pear    O
-    O
shaped    O
broad    O
nose    O
,    O
and    O
cone    O
-    O
shaped    O
epiphyses    O
of    O
the    O
middle    O
phalanges    O
of    O
some    O
fingers    O
and    O
toes    O
.    O

Parastremmatic    B-AutosomalDominantDisease114162025
dwarfism    I-AutosomalDominantDisease114162025
is    O
a    O
rare    O
bone    O
disease    O
that    O
features    O
severe    O
dwarfism    O
,    O
thoracic    O
kyphosis    O
(    O
a    O
type    O
of    O
scoliosis    O
that    O
affects    O
the    O
upper    O
back    O
)    O
,    O
a    O
distortion    O
and    O
twisting    O
of    O
the    O
limbs    O
,    O
contractures    O
of    O
the    O
large    O
joints    O
,    O
malformations    O
of    O
the    O
vertebrae    O
and    O
pelvis    O
,    O
and    O
incontinence    O
.    O

Marshall    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Marshall    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
is    O
a    O
genetic    O
disorder    O
of    O
the    O
connective    O
tissue    O
which    O
can    O
cause    O
hearing    O
loss    O
.    O

Piebaldism    B-AutosomalDominantDisease114162025

Piebaldism    B-AutosomalDominantDisease114162025
(    O
ILDS    O
E70.350    O
)    O

Piebaldism    B-AutosomalDominantDisease114162025

Activating    O
mutations    O
in    O
this    O
gene    O
are    O
associated    O
with    O
gastrointestinal    O
stromal    O
tumors    O
,    O
testicular    O
seminoma    O
,    O
mast    O
cell    O
disease    O
,    O
melanoma    O
,    O
acute    O
myeloid    O
leukemia    O
,    O
while    O
inactivating    O
mutations    O
are    O
associated    O
with    O
the    O
genetic    O
defect    O
piebaldism    B-AutosomalDominantDisease114162025
.    O

One    O
of    O
his    O
early    O
papers    O
was    O
his    O
description    O
of    O
two    O
siblings    O
with    O
lissencephaly    O
,    O
now    O
known    O
by    O
the    O
eponym    O
Miller-Dieker    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Miller-Dieker    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Spondyloepimetaphyseal    B-AutosomalDominantDisease114162025
dysplasia,    I-AutosomalDominantDisease114162025
Strudwick    I-AutosomalDominantDisease114162025
type    I-AutosomalDominantDisease114162025
:    O
All    O
of    O
the    O
mutations    O
in    O
the    O
COL2A1    O
gene    O
characterized    O
to    O
date    O
cause    O
an    O
amino    O
acid    O
switch    O
in    O
the    O
pro    O
-    O
alpha1(II    O
)    O
chain    O
of    O
type    O
II    O
collagen    O
;    O
specifically    O
,    O
the    O
amino    O
acid    O
glycine    O
is    O
replaced    O
by    O
a    O
different    O
amino    O
acid    O
.    O

NS    O
is    O
a    O
RASopathy    B-AutosomalDominantDisease114162025
,    O
and    O
is    O
one    O
of    O
several    O
disorders    O
that    O
are    O
caused    O
by    O
a    O
disruption    O
of    O
RAS    O
-    O
MAPK    O
signaling    O
pathway    O
.    O

Other    O
RASopathies    B-AutosomalDominantDisease114162025
,    O
particularly    O
:    O

The    O
genetic    O
abnormalities    O
underpinning    O
the    O
combination    O
of    O
DBA    O
with    O
Treacher    B-AutosomalDominantDisease114162025
Collins    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
(    O
TCS)/mandibulofacial    O
dysostosis    O
(    O
MFD    O
)    O
phenotypes    O
are    O
heterogeneous    O
,    O
including    O
RPS26    O
(    O
the    O
known    O
DBA10    O
gene    O
)    O
,    O
TSR2    O
which    O
encodes    O
a    O
direct    O
binding    O
partner    O
of    O
RPS26    O
,    O
and    O
RPS28    O
.    O

Techniques    O
for    O
correcting    O
Treacher    B-AutosomalDominantDisease114162025
Collins    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Such    O
as    O
Treacher    B-AutosomalDominantDisease114162025
Collins    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
Robin    O
sequence    O
,    O
head    O
and    O
neck    O
surgery    O
with    O
supraglottic    O
or    O
glottic    O
obstruction    O
)    O
.    O

He    O
was    O
a    O
famous    O
ophthalmologist    O
and    O
wrote    O
a    O
textbook    O
"    O
Diseases    O
of    O
the    O
Eye    O
"    O
(    O
1893    O
)    O
that    O
was    O
widely    O
used    O
in    O
the    O
U.K.    O
and    O
U.S.A.    O
In    O
1889    O
,    O
Berry    O
published    O
a    O
description    O
of    O
a    O
case    O
of    O
Treacher    B-AutosomalDominantDisease114162025
Collins    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
(    O
sometimes    O
called    O
Berry    O
-    O
Treacher    O
Collins    O
syndrome    O
)    O
.    O

The    O
combination    O
of    O
a    O
Tessier    O
number    O
6    O
-    O
7    O
-    O
8    O
is    O
seen    O
in    O
the    O
Treacher    B-AutosomalDominantDisease114162025
Collins    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Treacher    B-AutosomalDominantDisease114162025
Collins    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

X-linked    B-AutosomalDominantDisease114162025
recessive    I-AutosomalDominantDisease114162025
spinocerebellar    I-AutosomalDominantDisease114162025
ataxia    I-AutosomalDominantDisease114162025

Alternatively    O
,    O
overexpression    O
of    O
Hsp70    O
can    O
mitigate    O
damage    O
from    O
ischemia    O
-    O
reperfusion    O
in    O
cardiac    O
muscle    O
,    O
as    O
well    O
damage    O
from    O
neurodegenerative    O
diseases    O
,    O
such    O
as    O
Alzheimer    O
’s    O
disease    O
,    O
Parkinson    O
’s    O
disease    O
,    O
Huntington’s    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
and    O
spinocerebellar    B-AutosomalDominantDisease114162025
ataxias    I-AutosomalDominantDisease114162025
,    O
and    O
aging    O
and    O
cell    O
senescence    O
,    O
as    O
observed    O
in    O
centenarians    O
subjected    O
to    O
heat    O
shock    O
challenge    O
.    O

Mutations    O
that    O
expand    O
the    O
number    O
of    O
CAG    O
repeats    O
encoding    O
this    O
polyglutamine    O
tract    O
,    O
and    O
thus    O
increase    O
the    O
length    O
of    O
the    O
polyglutamine    O
string    O
,    O
are    O
associated    O
with    O
spinocerebellar    B-AutosomalDominantDisease114162025
ataxia    I-AutosomalDominantDisease114162025
17    O
,    O
a    O
neurodegenerative    O
disorder    O
classified    O
as    O
a    O
polyglutamine    O
disease    O
.    O

Spinocerebellar    B-AutosomalDominantDisease114162025
ataxia    I-AutosomalDominantDisease114162025

Her    O
work    O
has    O
elucidated    O
mechanisms    O
of    O
Rett    O
syndrome    O
and    O
spinocerebellar    B-AutosomalDominantDisease114162025
ataxias    I-AutosomalDominantDisease114162025
.    O

She    O
began    O
work    O
on    O
spinocerebellar    B-AutosomalDominantDisease114162025
ataxia    I-AutosomalDominantDisease114162025
type    I-AutosomalDominantDisease114162025
1    I-AutosomalDominantDisease114162025
(    O
SCA1    O
)    O
,    O
a    O
progressive    O
neurodegenerative    O
disorder    O
,    O
in    O
collaboration    O
with    O
Harry    O
Orr    O
at    O
the    O
University    O
of    O
Minnesota    O
.    O

Similarly    O
,    O
FXTAS    O
results    O
from    O
CGG    O
repeats    O
transcribed    O
from    O
a    O
region    O
in    O
the    O
FMR1    O
gene    O
encoding    O
protein    O
,    O
and    O
spinocerebellar    B-AutosomalDominantDisease114162025
ataxia    I-AutosomalDominantDisease114162025
(    O
SCA    O
)    O
results    O
from    O
CAG    O
repetition    O
transcribed    O
in    O
various    O
genes    O
.    O

Neuromuscular    O
problems    O
-    O
such    O
as    O
spinocerebellar    B-AutosomalDominantDisease114162025
ataxia    I-AutosomalDominantDisease114162025
and    O
myopathies    O
.    O

Dr.    O
Yamamoto    O
discovers    O
that    O
Aya    O
has    O
spinocerebellar    B-AutosomalDominantDisease114162025
ataxia    I-AutosomalDominantDisease114162025
,    O
a    O
fatal    O
and    O
incurable    O
disease    O
that    O
handicaps    O
the    O
body    O
.    O

Symptoms    O
include    O
a    O
combination    O
of    O
spinocerebellar    B-AutosomalDominantDisease114162025
degeneration    I-AutosomalDominantDisease114162025
and    O
corneal    O
dystrophy    O
.    O

is    O
a    O
2005    O
Japanese    O
television    O
drama    O
for    O
Fuji    O
Television    O
about    O
a    O
girl    O
who    O
was    O
diagnosed    O
with    O
an    O
incurable    O
degenerative    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
at    O
15    O
,    O
but    O
was    O
able    O
to    O
continue    O
her    O
life    O
until    O
her    O
death    O
at    O
the    O
age    O
of    O
25    O
.    O

Her    O
mother    O
Shioka    O
,    O
takes    O
Aya    O
to    O
see    O
the    O
doctor    O
,    O
and    O
he    O
informs    O
Shioka    O
that    O
Aya    O
has    O
spinocerebellar    B-AutosomalDominantDisease114162025
degeneration    I-AutosomalDominantDisease114162025
-    O
a    O
rare    O
disease    O
where    O
the    O
cerebellum    O
of    O
the    O
brain    O
gradually    O
deteriorates    O
to    O
the    O
point    O
where    O
the    O
victim    O
can    O
not    O
walk    O
,    O
speak    O
,    O
write    O
,    O
or    O
eat    O
.    O

Romano-Ward    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
is    O
an    O
autosomal    O
-    O
dominant    O
form    O
of    O
LQTS    O
not    O
associated    O
with    O
deafness    O
.    O

Jervell    O
and    O
Lange    O
-    O
Nielsen    O
syndrome    O
&    O
Romano-Ward    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
)    O
,    O
Brugada    O
,    O
Lev    O
-    O
Lenegre    O
's    O
Syndrome    O
)    O

Spondyloperipheral    B-AutosomalDominantDisease114162025
dysplasia    I-AutosomalDominantDisease114162025
:    O
Mutations    O
that    O
cause    O
spondyloperipheral    O
dysplasia    O
lead    O
to    O
the    O
production    O
of    O
an    O
abnormally    O
short    O
pro    O
-    O
alpha1(II    O
)    O
chain    O
that    O
can    O
not    O
be    O
incorporated    O
into    O
type    O
II    O
collagen    O
fibers    O
.    O

Collagen    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
is    O
a    O
term    O
previously    O
used    O
to    O
describe    O
systemic    O
autoimmune    O
diseases    O
(    O
e.g.    O
,    O
rheumatoid    O
arthritis    O
,    O
systemic    O
lupus    O
erythematosus    O
,    O
and    O
systemic    O
sclerosis    O
)    O
,    O
but    O
now    O
is    O
thought    O
to    O
be    O
more    O
appropriate    O
for    O
diseases    O
associated    O
with    O
defects    O
in    O
collagen    O
,    O
which    O
is    O
a    O
component    O
of    O
the    O
connective    O
tissue    O
.    O

In    O
the    O
field    O
of    O
dermatology    O
,    O
the    O
Naegeli    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
is    O
named    O
after    O
him    O
.    O

Reduced    O
or    O
absent    O
aggregation    O
in    O
response    O
to    O
ristocetin    O
can    O
be    O
caused    O
by    O
a    O
lack    O
of    O
or    O
reduction    O
of    O
vWF    O
,    O
as    O
seen    O
in    O
von    B-AutosomalDominantDisease114162025
Willebrand    I-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
(    O
vWD    O
)    O
,    O
or    O
absence    O
or    O
reduction    O
in    O
numbers    O
of    O
GP1b    O
receptors    O
,    O
as    O
in    O
Bernard    O
-    O
Soulier    O
syndrome    O
(    O
BSS    O
)    O
.    O

It    O
is    O
similar    O
to    O
the    O
ristocetin    O
cofactor    O
assay    O
but    O
has    O
the    O
added    O
benefit    O
in    O
that    O
it    O
helps    O
in    O
the    O
diagnosis    O
of    O
type    O
2B    O
/    O
pseudo    O
von    B-AutosomalDominantDisease114162025
Willebrand    I-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
(    O
vWD    O
)    O
and    O
Bernard    O
-    O
Soulier    O
syndrome    O
because    O
it    O
uses    O
patient    O
's    O
live    O
endogenous    O
platelets    O
,    O
whereas    O
ristocetin    O
cofactor    O
assay    O
tests    O
the    O
function    O
of    O
only    O
the    O
vWF    O
and    O
not    O
the    O
platelets    O
.    O

hip    O
dysplasia    O
,    O
cancer    O
,    O
progressive    O
retinal    O
atrophy    O
(    O
PRA    O
)    O
,    O
epilepsy    O
,    O
entropion    O
,    O
hypothyroidism    O
,    O
hyperosteodystrophy    O
,    O
gastric    O
dilatation    O
volvulus    O
(    O
bloat    O
)    O
,    O
osteosarcoma    O
,    O
Von    B-AutosomalDominantDisease114162025
Willebrand's    I-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
patent    O
ductus    O
arteriosus    O
,    O
canine    O
Leukocyte    O
adhesion    O
deficiency    O
(    O
CLAD    O
)    O
and    O
celiac    O
disease    O
.    O

von    B-AutosomalDominantDisease114162025
Willebrands    I-AutosomalDominantDisease114162025
Disease    I-AutosomalDominantDisease114162025
(    O
vWD    O
)    O
–    O
a    O
failure    O
of    O
the    O
blood    O
to    O
clot    O
over    O
a    O
wound    O
,    O
which    O
in    O
extreme    O
cases    O
,    O
the    O
dog    O
can    O
bleed    O
to    O
death    O
with    O
only    O
a    O
small    O
wound    O
,    O
if    O
unattended    O
.    O

Von    B-AutosomalDominantDisease114162025
Willebrand    I-AutosomalDominantDisease114162025
Disease    I-AutosomalDominantDisease114162025

von    B-AutosomalDominantDisease114162025
Willebrand    I-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
(    O
vWD    O
)    O
(    O
Bleeding    O
disorder    O
)    O

#    O
von    B-AutosomalDominantDisease114162025
Willebrand    I-AutosomalDominantDisease114162025

An    O
autopsy    O
at    O
the    O
time    O
of    O
her    O
death    O
concluded    O
she    O
died    O
from    O
an    O
intra    O
-    O
cerebral    O
haemorrhage    O
secondary    O
to    O
the    O
blood    O
coagulation    O
disorder    O
Von    B-AutosomalDominantDisease114162025
Willebrand's    I-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
,    O
based    O
on    O
blood    O
in    O
her    O
cerebrospinal    O
fluid    O
and    O
reports    O
that    O
she    O
had    O
been    O
suffering    O
severe    O
,    O
persistent    O
headaches    O
in    O
the    O
weeks    O
leading    O
up    O
to    O
her    O
death    O
.    O

Haematology    O
:    O
high    O
-    O
purity    O
coagulation    O
factor    O
concentrates    O
for    O
patients    O
with    O
bleeding    O
disorders    O
Haemophilia    O
A    O
,    O
B    O
and    O
von    B-AutosomalDominantDisease114162025
Willebrand    I-AutosomalDominantDisease114162025
Disease    I-AutosomalDominantDisease114162025
.    O

Von    B-AutosomalDominantDisease114162025
Willebrand    I-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025

A    O
gain    O
-    O
of    O
-    O
function    O
mutation    O
causes    O
platelet    O
-    O
type    O
von    B-AutosomalDominantDisease114162025
Willebrand's    I-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025
.    O

American    O
endocrinologist    O
Grant    O
Liddle    O
identifies    O
Liddle's    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Gain    O
of    O
function    O
mutations    O
to    O
the    O
β    O
and    O
γ    O
subunits    O
are    O
associated    O
with    O
Liddle's    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Short    B-AutosomalDominantDisease114162025
QT    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Using    O
genetic    O
sequencing    O
techniques    O
,    O
scientists    O
at    O
the    O
MMRL    O
are    O
studying    O
inherited    O
cardiac    O
arrhythmia    O
syndromes    O
,    O
including    O
sudden    O
cardiac    O
death    O
syndromes    O
such    O
as    O
the    O
Long    O
QT    O
syndrome    O
,    O
Short    B-AutosomalDominantDisease114162025
QT    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
Brugada    O
syndrome    O
and    O
Early    O
Repolarization    O
syndrome    O
.    O

This    O
isoform    O
is    O
identified    O
as    O
an    O
autoantigen    O
in    O
66%    O
of    O
patients    O
with    O
Felty's    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Felty's    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

PVS    O
was    O
the    O
key    O
finding    O
that    O
led    O
Jacqueline    O
Noonan    O
to    O
identify    O
the    O
syndrome    O
now    O
called    O
Noonan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

The    O
diagnosis    O
of    O
pulmonary    O
valve    O
stenosis    O
can    O
be    O
achieved    O
via    O
echocardiogram    O
,    O
as    O
well    O
as    O
a    O
variety    O
of    O
other    O
means    O
among    O
them    O
are    O
:    O
ultrasound    O
,    O
in    O
which    O
images    O
of    O
the    O
heart    O
chambers    O
in    O
utero    O
where    O
the    O
tricuspid    O
valve    O
has    O
thickening    O
(    O
or    O
due    O
to    O
Fallot    O
's    O
tetralogy    O
,    O
Noonan's    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
and    O
other    O
congenital    O
defects    O
)    O
and    O
in    O
infancy    O
auscultation    O
of    O
the    O
heart    O
can    O
reveal    O
identification    O
of    O
a    O
murmur    O
.    O

Factors    O
that    O
increase    O
the    O
likelihood    O
of    O
this    O
cancer    O
include    O
Li    O
-    O
Fraumeni    O
syndrome    O
,    O
type    O
one    O
Neurofibromatosis    O
,    O
Beckwith    O
-    O
Wiedemann    O
syndrome    O
,    O
Costello    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
and    O
Noonan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Noonan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Noonan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
(    O
NS    B-AutosomalDominantDisease114162025
)    O
is    O
a    O
relatively    O
common    O
autosomal    O
dominant    O
congenital    O
disorder    O
and    O
is    O
named    O
after    O
Jacqueline    O
Noonan    O
,    O
a    O
pediatric    O
cardiologist    O
.    O

The    O
top    O
two    O
syndromic    O
causes    O
of    O
congenital    O
heart    O
defects    O
are    O
Noonan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
and    O
Down    O
syndrome    O
.    O

Narrowing    O
of    O
the    O
pulmonary    O
valve    O
that    O
is    O
the    O
key    O
finding    O
in    O
Noonan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Jacqueline    O
Noonan    O
(    O
born    O
1928    O
)    O
–    O
discoverer    O
of    O
Noonan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
that    O
is    O
the    O
top    O
syndromic    O
cause    O
of    O
congenital    O
heart    O
disease    O

Dyschronometria    O
can    O
result    O
from    O
autosomal    B-AutosomalDominantDisease114162025
dominant    I-AutosomalDominantDisease114162025
cerebellar    I-AutosomalDominantDisease114162025
ataxia    I-AutosomalDominantDisease114162025
(    O
ADCA    O
)    O
.    O

Multiple    B-AutosomalDominantDisease114162025
endocrine    I-AutosomalDominantDisease114162025
neoplasia    I-AutosomalDominantDisease114162025
type    I-AutosomalDominantDisease114162025
2a    I-AutosomalDominantDisease114162025

Multiple    B-AutosomalDominantDisease114162025
endocrine    I-AutosomalDominantDisease114162025
neoplasia    I-AutosomalDominantDisease114162025
type    I-AutosomalDominantDisease114162025
2    I-AutosomalDominantDisease114162025
(    O
MEN2    B-AutosomalDominantDisease114162025
)    O
(    O
also    O
known    O
as    O
"    O
Pheochromocytoma    O
and    O
amyloid    O
producing    O
medullary    O
thyroid    O
carcinoma    O
"    O
,    O
"    O
PTC    O
syndrome    O
,    O
"    O
and    O
"    O
Sipple    O
syndrome    O
"    O
)    O
is    O
a    O
group    O
of    O
medical    O
disorders    O
associated    O
with    O
tumors    O
of    O
the    O
endocrine    O
system    O
.    O

MEN2    O
includes    O
MEN2A    B-AutosomalDominantDisease114162025
,    O
MEN2B    B-AutosomalDominantDisease114162025
and    O
familial    O
medullary    O
thyroid    O
cancer    O
(    O
FMTC    O
)    O
.    O

While    O
these    O
neoplasias    O
are    O
often    O
benign    O
(    O
in    O
contrast    O
to    O
tumours    O
occurring    O
in    O
MEN2A    B-AutosomalDominantDisease114162025
)    O
,    O
they    O
are    O
adenomas    O
and    O
,    O
therefore    O
,    O
produce    O
endocrine    O
phenotypes    O
.    O

Hereditary    B-AutosomalDominantDisease114162025
haemorrhagic    I-AutosomalDominantDisease114162025
telangiectasia    I-AutosomalDominantDisease114162025

Non    O
-    O
infectious    O
diseases    O
that    O
can    O
be    O
confused    O
with    O
MVD    O
are    O
acute    O
promyelocytic    O
leukemia    O
,    O
hemolytic    O
uremic    O
syndrome    O
,    O
snake    O
envenomation    O
,    O
clotting    O
factor    O
deficiencies    O
/    O
platelet    O
disorders    O
,    O
thrombotic    O
thrombocytopenic    O
purpura    O
,    O
hereditary    B-AutosomalDominantDisease114162025
hemorrhagic    I-AutosomalDominantDisease114162025
telangiectasia    I-AutosomalDominantDisease114162025
,    O
Kawasaki    O
disease    O
,    O
and    O
even    O
warfarin    O
intoxication    O
.    O

Non    O
-    O
infectious    O
diseases    O
that    O
may    O
result    O
in    O
symptoms    O
similar    O
to    O
those    O
of    O
EVD    O
include    O
acute    O
promyelocytic    O
leukemia    O
,    O
hemolytic    O
uremic    O
syndrome    O
,    O
snake    O
envenomation    O
,    O
clotting    O
factor    O
deficiencies    O
/    O
platelet    O
disorders    O
,    O
thrombotic    O
thrombocytopenic    O
purpura    O
,    O
hereditary    B-AutosomalDominantDisease114162025
hemorrhagic    I-AutosomalDominantDisease114162025
telangiectasia    I-AutosomalDominantDisease114162025
,    O
Kawasaki    O
disease    O
,    O
and    O
warfarin    O
poisoning    O
.    O

hereditary    B-AutosomalDominantDisease114162025
hemorrhagic    I-AutosomalDominantDisease114162025
telangiectasia    I-AutosomalDominantDisease114162025
and    O

Hereditary    B-AutosomalDominantDisease114162025
hemorrhagic    I-AutosomalDominantDisease114162025
telangiectasia    I-AutosomalDominantDisease114162025

It    O
may    O
occur    O
in    O
situations    O
with    O
an    O
increased    O
blood    O
volume    O
,    O
from    O
excess    O
of    O
water    O
and    O
salt    O
(    O
kidney    O
pathology    O
,    O
excess    O
of    O
fluid    O
or    O
blood    O
administration    O
,    O
treatment    O
with    O
retaining    O
water    O
steroids    O
)    O
,    O
chronic    O
and    O
severe    O
anemia    O
,    O
large    O
arteriovenous    O
fistula    O
or    O
multiple    O
small    O
arteriovenous    O
shunts    O
as    O
in    O
HHT    B-AutosomalDominantDisease114162025
or    O
Paget    O
's    O
disease    O
of    O
bone    O
,    O
some    O
forms    O
of    O
severe    O
liver    O
or    O
kidney    O
disorders    O
,    O
hyperthyroidism    O
,    O
and    O
wet    O
beriberi    O
,    O
and    O
acutely    O
in    O
septic    O
shock    O
,    O
especially    O
caused    O
by    O
Gram    O
-    O
negative    O
bacteria    O
.    O

Dysplasia    O
Epiphysealis    O
Hemimelica    O
(    O
DEH    O
)    O
or    O
Trevor    O
's    O
disease    O
and    O
metachondromatosis    B-AutosomalDominantDisease114162025
(    O
MC    O
)    O
are    O
considered    O
differential    O
diagnosis    O
of    O
both    O
solitary    O
and    O
hereditary    O
osteochondromas    O
.    O

Kostmann's    B-AutosomalDominantDisease114162025
disease    I-AutosomalDominantDisease114162025

Intrinsic    O
disorders    O
-    O
Fanconi    O
's    O
,    O
Kostmann's    B-AutosomalDominantDisease114162025
,    O
cyclic    O
neutropenia    O
,    O
Chédiak    O

Hereditary    B-AutosomalDominantDisease114162025
spherocytosis    I-AutosomalDominantDisease114162025
,    O
a    O
genetic    O
disorder    O
marked    O
by    O
hemolytic    O
anemia    O

Hereditary    B-AutosomalDominantDisease114162025
spherocytosis    I-AutosomalDominantDisease114162025

Minkowski-Chauffard    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Spleens    O
are    O
also    O
removed    O
for    O
therapeutic    O
purposes    O
in    O
conditions    O
like    O
hereditary    B-AutosomalDominantDisease114162025
spherocytosis    I-AutosomalDominantDisease114162025
,    O
trauma    O
to    O
the    O
spleen    O
,    O
and    O
autosplenectomy    O
caused    O
by    O
sickle    O
cell    O
anemia    O
.    O

After    O
clinical    O
training    O
,    O
Agre    O
joined    O
Vann    O
Bennett    O
’s    O
lab    O
in    O
the    O
Cell    O
Biology    O
Department    O
at    O
Johns    O
Hopkins    O
where    O
he    O
studied    O
red    O
cell    O
membranes    O
and    O
identified    O
spectrin    O
deficiency    O
as    O
a    O
common    O
cause    O
of    O
hereditary    B-AutosomalDominantDisease114162025
spherocytosis    I-AutosomalDominantDisease114162025
,    O
a    O
hemolytic    O
anemia    O
with    O
fragile    O
,    O
spherically    O
shaped    O
red    O
cells    O
.    O

Genetically    O
,    O
PECs    O
are    O
linked    O
to    O
the    O
tuberous    B-AutosomalDominantDisease114162025
sclerosis    I-AutosomalDominantDisease114162025
genes    O
TSC1    O
and    O
TSC2    O
,    O
although    O
this    O
link    O
is    O
stronger    O
for    O
angiomyolipoma    O
and    O
lymphangioleiomyomatosis    O
than    O
for    O
other    O
members    O
of    O
the    O
PEComa    O
family    O
.    O

Angiomyolipomas    O
are    O
strongly    O
associated    O
with    O
the    O
genetic    O
disease    O
tuberous    B-AutosomalDominantDisease114162025
sclerosis    I-AutosomalDominantDisease114162025
,    O
in    O
which    O
most    O
individuals    O
will    O
have    O
several    O
angiomyolipomas    O
affecting    O
both    O
kidneys    O
.    O

LAM    O
involves    O
lung    O
tissue    O
infiltration    O
with    O
smooth    O
muscle    O
-    O
like    O
cells    O
with    O
mutations    O
of    O
the    O
tuberous    B-AutosomalDominantDisease114162025
sclerosis    I-AutosomalDominantDisease114162025
complex    I-AutosomalDominantDisease114162025
gene    O
(    O
TSC2    O
)    O
.    O

Sirolimus    O
also    O
shows    O
promise    O
in    O
treating    O
tuberous    B-AutosomalDominantDisease114162025
sclerosis    I-AutosomalDominantDisease114162025
complex    I-AutosomalDominantDisease114162025
(    O
TSC    O
)    O
,    O
a    O
congenital    O
disorder    O
that    O
leaves    O
sufferers    O
prone    O
to    O
benign    O
tumor    O
growth    O
in    O
the    O
brain    O
,    O
heart    O
,    O
kidneys    O
,    O
skin    O
,    O
and    O
other    O
organs    O
.    O

Facial    B-AutosomalDominantDisease114162025
angiofibromas    I-AutosomalDominantDisease114162025
occur    O
in    O
80%    O
of    O
patients    O
with    O
TSC    O
,    O
and    O
the    O
condition    O
is    O
very    O
disfiguring    O
.    O

It    O
is    O
marketed    O
by    O
Novartis    O
under    O
the    O
trade    O
names    O
Zortress    O
(    O
USA    O
)    O
and    O
Certican    O
(    O
Europe    O
and    O
other    O
countries    O
)    O
in    O
transplantation    O
medicine    O
,    O
and    O
as    O
Afinitor    O
(    O
general    O
tumours    O
)    O
and    O
Votubia    O
(    O
tumours    O
as    O
a    O
result    O
of    O
TSC    B-AutosomalDominantDisease114162025
)    O
in    O
oncology    O
.    O

Subependymal    O
giant    O
cell    O
astrocytoma    O
(    O
SEGA    O
)    O
associated    O
with    O
tuberous    B-AutosomalDominantDisease114162025
sclerosis    I-AutosomalDominantDisease114162025
(TS)    I-AutosomalDominantDisease114162025
in    O
patients    O
who    O
are    O
not    O
suitable    O
for    O
surgical    O
intervention    O
(    O
US    O
FDA    O
October    O
2010    O
)    O

NHS    O
England    O
has    O
been    O
criticised    O
for    O
delays    O
in    O
deciding    O
on    O
a    O
policy    O
for    O
the    O
prescription    O
of    O
everolimus    O
in    O
the    O
treatment    O
of    O
Tuberous    B-AutosomalDominantDisease114162025
Sclerosis    I-AutosomalDominantDisease114162025
.    O

TSC1    O
and    O
TSC2    O
,    O
the    O
genes    O
involved    O
in    O
tuberous    B-AutosomalDominantDisease114162025
sclerosis    I-AutosomalDominantDisease114162025
,    O
act    O
as    O
tumor    O
suppressor    O
genes    O
by    O
regulating    O
mTORC1    O
activity    O
.    O

The    O
journal    O
covers    O
research    O
on    O
neurodevelopmental    O
disorders    O
including    O
autism    O
spectrum    O
disorders    O
,    O
tuberous    B-AutosomalDominantDisease114162025
sclerosis    I-AutosomalDominantDisease114162025
,    O
and    O
specific    O
language    O
impairment    O
.    O

These    O
multifocal    O
lesions    O
are    O
observed    O
in    O
tuberous    B-AutosomalDominantDisease114162025
sclerosis    I-AutosomalDominantDisease114162025
,    O
and    O
can    O
be    O
associated    O
with    O
lymphangioleiomyomatosis    O
and    O
perivascular    O
epithelioid    O
cell    O
tumour    O
(    O
PEComa    O
or    O
clear    O
cell    O
"    O
sugar    O
tumor    O
"    O
)    O
)    O
.    O

Tuberous    B-AutosomalDominantDisease114162025
sclerosis    I-AutosomalDominantDisease114162025

He    O
published    O
papers    O
on    O
tuberous    B-AutosomalDominantDisease114162025
sclerosis    I-AutosomalDominantDisease114162025
and    O
Batten    O
disease    O
,    O
and    O
was    O
the    O
author    O
of    O
a    O
handbook    O
on    O
the    O
treatment    O
of    O
nervous    O
diseases    O
.    O

Aromatase    B-AutosomalDominantDisease114162025
excess    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
an    O
extremely    O
rare    O
condition    O
characterized    O
by    O
marked    O
hyperestrogenism    O
,    O
is    O
associated    O
with    O
precocious    O
breast    O
development    O
and    O
macromastia    O
in    O
females    O
and    O
similarly    O
precocious    O
gynecomastia    O
(    O
women    O
's    O
breasts    O
)    O
in    O
males    O
.    O

The    O
functional    O
opposite    O
of    O
EIS    O
is    O
hyperestrogenism    O
,    O
for    O
instance    O
that    O
seen    O
in    O
aromatase    B-AutosomalDominantDisease114162025
excess    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Aromatase    B-AutosomalDominantDisease114162025
excess    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

He    O
was    O
a    O
dwarf    O
,    O
due    O
to    O
spondyloepiphyseal    B-AutosomalDominantDisease114162025
dysplasia    I-AutosomalDominantDisease114162025
congenita    I-AutosomalDominantDisease114162025
.    O

Spondyloepiphyseal    B-AutosomalDominantDisease114162025
dysplasia    I-AutosomalDominantDisease114162025

Davis    O
inherited    O
spondyloepiphyseal    B-AutosomalDominantDisease114162025
dysplasia    I-AutosomalDominantDisease114162025
congenita    I-AutosomalDominantDisease114162025
from    O
her    O
father    O
.    O

Anorectal    O
malformation    O
in    O
Currarino    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
represents    O
the    O
only    O
association    O
for    O
which    O
the    O
gene    O
HLXB9    O
has    O
been    O
identified    O
.    O

Other    O
entities    O
associated    O
with    O
an    O
imperforate    O
anus    O
are    O
trisomies    O
18    O
and    O
21    O
,    O
the    O
cat    O
-    O
eye    O
syndrome    O
(    O
partial    O
trisomy    O
or    O
tetrasomy    O
of    O
a    O
maternally    O
derived    O
number    O
22    O
chromosome    O
)    O
,    O
Baller    O
-    O
Gerold    O
syndrome    O
,    O
Currarino    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
caudal    O
regression    O
syndrome    O
,    O
FG    O
syndrome    O
,    O
Johanson    O
-    O
Blizzard    O
syndrome    O
,    O
McKusick    O
-    O
Kaufman    O
syndrome    O
,    O
Pallister-Hall    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
short    O
rib    O
-    O
polydactyly    O
syndrome    O
type    O
1    O
,    O
Townes    O
-    O
Brocks    O
syndrome    O
,    O
13q    O
deletion    O
syndrome    O
,    O
urorectal    O
septum    O
malformation    O
sequence    O
,    O
and    O
the    O
OEIS    O
complex    O
(    O
omphalocele    O
,    O
exstrophy    O
of    O
the    O
cloaca    O
,    O
imperforate    O
anus    O
,    O
spinal    O
defects    O
)    O
.    O

PAPA    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

PAPA    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
is    O
an    O
acronym    O
for    O
pyogenic    O
arthritis    O
,    O
pyoderma    O
gangrenosum    O
and    O
acne    O
.    O

A    O
rare    O
genetic    O
disorder    O
,    O
Singleton    B-AutosomalDominantDisease114162025
Merten    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
is    O
named    O
in    O
part    O
after    O
him    O
.    O

Several    O
candidate    O
genes    O
(    O
such    O
as    O
FBN1    O
,    O
which    O
has    O
been    O
associated    O
with    O
Marfan    B-AutosomalDominantDisease114162025
)    O
have    O
been    O
proposed    O
and    O
excluded    O
.    O

Patients    O
who    O
exhibit    O
extreme    O
joint    O
hypermobility    O
and    O
connective    O
tissue    O
weakness    O
as    O
a    O
result    O
of    O
Ehlers    O
-    O
Danlos    O
syndrome    O
or    O
Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
are    O
susceptible    O
to    O
instabilities    O
of    O
the    O
craniocervical    O
junction    O
;    O
thus    O
they    O
are    O
at    O
risk    O
for    O
acquiring    O
a    O
Chiari    O
malformation    O
.    O

Other    O
conditions    O
sometimes    O
associated    O
with    O
Chiari    O
malformation    O
include    O
hydrocephalus    O
,    O
syringomyelia    O
,    O
spinal    O
curvature    O
,    O
tethered    O
spinal    O
cord    O
syndrome    O
,    O
and    O
connective    O
tissue    O
disorders    O
such    O
as    O
Ehlers    O
-    O
Danlos    O
syndrome    O
and    O
Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

About    O
1957    O
she    O
began    O
using    O
a    O
wheelchair    O
,    O
after    O
battling    O
with    O
Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
throughout    O
her    O
life    O
.    O

Marfan's    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

A    O
Type    O
1    O
collagen    O
or    O
other    O
connective    O
tissue    O
defect    O
(    O
as    O
found    O
in    O
Ehlers    O
-    O
Danlos    O
syndrome    O
,    O
Loeys    O
-    O
Dietz    O
syndrome    O
and    O
Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
)    O
resulting    O
in    O
weakened    O
ligaments    O
/    O
ligamentous    O
laxity    O
,    O
muscles    O
and    O
tendons    O
.    O

Hypermobility    O
may    O
be    O
symptomatic    O
of    O
a    O
serious    O
medical    O
condition    O
,    O
such    O
as    O
Stickler    B-AutosomalDominantDisease114162025
Syndrome    I-AutosomalDominantDisease114162025
,    O
Ehlers    O
-    O
Danlos    O
syndrome    O
,    O
Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
Loeys    O
-    O
Dietz    O
syndrome    O
,    O
rheumatoid    O
arthritis    O
,    O
osteogenesis    O
imperfecta    O
,    O
lupus    O
,    O
polio    O
,    O
Down    O
syndrome    O
,    O
morquio    O
syndrome    O
,    O
cleidocranial    O
dysostosis    O
or    O
myotonia    O
congenita    O
.    O

Hypermobility    O
can    O
also    O
be    O
caused    O
by    O
connective    O
tissue    O
disorders    O
,    O
such    O
as    O
Ehlers    O
-    O
Danlos    O
Syndrome    O
(    O
EDS    O
)    O
and    O
Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

He    O
is    O
also    O
known    O
as    O
"    O
El    O
Flaco    O
"    O
(    O
the    O
thin    O
guy    O
)    O
Silva    O
,    O
after    O
his    O
body    O
shape    O
(    O
see    O
Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
)    O
.    O

Antoine    O
Marfan    O
first    O
describes    O
the    O
symptoms    O
of    O
Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Marfan's    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
is    O
caused    O
by    O
mutations    O
in    O
the    O
"    O
FBN1    O
"    O
gene    O
,    O
located    O
on    O
chromosome    O
15    O
,    O
which    O
encodes    O
fibrillin-1    O
,    O
a    O
glycoprotein    O
component    O
of    O
the    O
extracellular    O
matrix    O
.    O

Medical    O
DNA    O
purification    O
techniques    O
have    O
allowed    O
humanity    O
to    O
rid    O
themselves    O
of    O
the    O
once    O
pesky    O
and    O
sometimes    O
fatal    O
hereditary    O
illnesses    O
like    O
Marfan's    B-AutosomalDominantDisease114162025
Syndrome    I-AutosomalDominantDisease114162025
,    O
Down    O
syndrome    O
and    O
Muscular    O
Dystrophy    O
creating    O
areas    O
of    O
the    O
world    O
where    O
these    O
diseases    O
are    O
entirely    O
extinct    O
.    O

It    O
is    O
a    O
common    O
feature    O
of    O
several    O
kinds    O
of    O
hereditary    O
disorders    O
which    O
affect    O
connective    O
tissue    O
,    O
such    O
as    O
Marfan    B-AutosomalDominantDisease114162025
Syndrome    I-AutosomalDominantDisease114162025
and    O
homocystinuria    O
.    O

Several    O
other    O
congenital    O
disorders    O
can    O
also    O
lead    O
to    O
bronchiectasis    O
,    O
including    O
Williams    O
-    O
Campbell    O
syndrome    O
and    O
Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Marfan    B-AutosomalDominantDisease114162025
Syndrome    I-AutosomalDominantDisease114162025

His    O
height    O
is    O
not    O
a    O
product    O
of    O
gigantism    O
"    O
I    O
do    O
n't    O
have    O
the    O
big    O
head    O
"    O
but    O
of    O
a    O
connective    O
tissue    O
disorder    O
called    O
Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O

Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Marfan    B-AutosomalDominantDisease114162025
Syndrome    I-AutosomalDominantDisease114162025

Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

There    O
is    O
an    O
association    O
between    O
familial    O
thoracic    O
aortic    O
aneurysm    O
,    O
Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
and    O
massive    O
baclofen    O
overdose    O
as    O
well    O
as    O
other    O
hereditary    O
connective    O
tissue    O
disorders    O
.    O

Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
-    O
long    O
limbs    O
to    O
height    O
ratio    O

They    O
are    O
associated    O
with    O
a    O
smoking    O
history    O
and    O
in    O
connective    O
tissue    O
diseases    O
(    O
e.g.    O
,    O
Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
Ehlers    O
-    O
Danlos    O
syndrome    O
)    O
.    O

Tarlov    O
perineural    O
cysts    O
have    O
occasionally    O
been    O
observed    O
in    O
patients    O
with    O
Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
Ehlers    O
-    O
Danlos    O
syndrome    O
,    O
and    O
Loeys    O
-    O
Dietz    O
syndrome    O
.    O

Marfan    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

There    O
is    O
evidence    O
tying    O
it    O
to    O
Greenberg    O
dysplasia    O
and    O
Pelger-Huet    B-AutosomalDominantDisease114162025
anomaly    I-AutosomalDominantDisease114162025
.    O

Pelger–Huet    B-AutosomalDominantDisease114162025
anomaly    I-AutosomalDominantDisease114162025

Papillorenal    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
also    O
called    O
renal-coloboma    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
or    O
isolated    B-AutosomalDominantDisease114162025
renal    I-AutosomalDominantDisease114162025
hypoplasia    I-AutosomalDominantDisease114162025
,    O
is    O
an    O
autosomal    O
dominant    O
genetic    O
disorder    O
marked    O
by    O
underdevelopment    O
(    O
hypoplasia    O
)    O
of    O
the    O
kidney    O
and    O
colobomas    O
of    O
the    O
optic    O
nerve    O
.    O

22q11.2    O
distal    O
deletion    O
syndrome    O
appears    O
to    O
be    O
a    O
recurrent    O
genomic    O
disorder    O
distinct    O
from    O
DiGeorge    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
(    O
DGS    O
;    O
188400    O
)    O
and    O
velocardiofacial    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
(    O
VCFS    O
;    O
192430    O
)    O
.    O

22q11.2    B-AutosomalDominantDisease114162025
deletion    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

"    O
Partial    O
insufficiencies    O
"    O
of    O
T    O
cell    O
function    O
include    O
acquired    O
immune    O
deficiency    O
syndrome    O
(    O
AIDS    O
)    O
,    O
and    O
hereditary    O
conditions    O
such    O
as    O
DiGeorge    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
(    O
DGS    O
)    O
,    O
chromosomal    O
breakage    O
syndromes    O
(    O
CBSs    O
)    O
,    O
and    O
B    O
-    O
cell    O
and    O
T    O
-    O
cell    O
combined    O
disorders    O
such    O
as    O
ataxia    O
-    O
telangiectasia    O
(    O
AT    O
)    O
and    O
Wiskott    O
–    O
Aldrich    O
syndrome    O
(    O
WAS    O
)    O
.    O

DiGeorge    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
is    O
first    O
described    O
by    O
pediatric    O
endocrinologist    O
Angelo    O
DiGeorge    O
.    O

DiGeorge    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
or    O
velocardiofacial    O
syndrome    O
–    O
most    O
common    O
microdeletion    O
syndrome    O

DiGeorge    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Di    B-AutosomalDominantDisease114162025
George's    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

A    O
few    O
examples    O
of    O
loci    O
that    O
have    O
been    O
studied    O
are    O
the    O
17q21    O
region    O
,    O
the    O
3p24    O
-    O
26    O
locus    O
,    O
PTEN    O
,    O
15q11.2–q13    O
and    O
deletion    O
in    O
the    O
22q11.2    B-AutosomalDominantDisease114162025
area    O
.    O

However    O
,    O
increased    O
nuchal    O
translucency    O
measurements    O
are    O
also    O
associated    O
with    O
non    O
-    O
chromosomal    O
abnormalities    O
such    O
as    O
genetic    O
conditions    O
(    O
e.g.    O
Di    B-AutosomalDominantDisease114162025
George    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
)    O
and    O
non    O
-    O
genetic    O
ones    O
(    O
e.g.    O
Body    O
-    O
stalk    O
anomaly    O
)    O
.    O

The    O
gene    O
coding    O
for    O
C22orf25    O
is    O
located    O
on    O
chromosome    O
22    O
and    O
the    O
location    O
q11.21    O
,    O
so    O
it    O
is    O
often    O
associated    O
with    O
22q11.2    B-AutosomalDominantDisease114162025
deletion    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
.    O

There    O
is    O
a    O
1.5    O
-    O
3.0    O
Mb    O
deletion    O
containing    O
around    O
30    O
-    O
40    O
genes    O
,    O
spanning    O
this    O
region    O
that    O
causes    O
the    O
most    O
survivable    O
genetic    O
deletion    O
disorder    O
known    O
as    O
22q11.2    B-AutosomalDominantDisease114162025
deletion    I-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
,    O
which    O
is    O
most    O
commonly    O
known    O
as    O
DiGeorge    O
syndrome    O
or    O
Velocaridofacial    O
syndrome    O
.    O

Thymic    O
hypoplasia    O
as    O
may    O
be    O
seen    O
in    O
DiGeorge    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025
results    O
in    O
no    O
T    O
-    O
cell    O
education    O
,    O
and    O
therefore    O
a    O
severe    O
compromise    O
in    O
T    O
-    O
cell    O
-    O
mediated    O
and    O
humoral    O
responses    O
.    O

Caused    O
by    O
glycoprotein    O
abnormalities    O
:    O
Bernard    O
-    O
Soulier    O
syndrome    O
,    O
Velocardiofacial    B-AutosomalDominantDisease114162025
syndrome    I-AutosomalDominantDisease114162025

Kniest    B-AutosomalDominantDisease114162025
dysplasia    I-AutosomalDominantDisease114162025
:    O
Most    O
of    O
the    O
mutations    O
responsible    O
for    O
Kniest    O
dysplasia    O
cause    O
abnormally    O
short    O
pro    O
-    O
alpha1(II    O
)    O
collagen    O
chains    O
to    O
be    O
produced    O
in    O
the    O
cell    O
.    O


